Coronavirus disease 2019 (COVID-19)

World Health Organization. Clinical management of COVID-19: living guideline, 18 August 2023. Aug 2023 [internet publication].Full text

National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. May 2024 [internet publication].Full text

World Health Organization. Therapeutics and COVID-19: living guideline. Nov 2023 [internet publication].Full text

Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Jun 2023 [internet publication].Full text

1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr;5(4):536-44.Full text  Abstract

2. World Health Organization. Tracking SARS-CoV-2 variants. Jun 2024 [internet publication].Full text

3. UK Health Security Agency. Investigation of SARS-CoV-2 variants: technical briefings. Sep 2023 [internet publication].Full text

4. Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions. Sep 2023 [internet publication].Full text

5. World Health Organization. Updated working definitions and primary actions for SARS-CoV-2 variants. Oct 2023 [internet publication].Full text

6. Nyberg T, Twohig KA, Harris RJ, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ. 2021 Jun 15;373:n1412.Full text  Abstract

7. Bager P, Wohlfahrt J, Fonager J, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1507-17.Full text  Abstract

8. Patone M, Thomas K, Hatch R, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. Lancet Infect Dis. 2021 Nov;21(11):1518-28.Full text  Abstract

9. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-45.Full text  Abstract

10. Butt AA, Dargham SR, Chemaitelly H, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern Med. 2022 Feb 1;182(2):197-205.Full text  Abstract

11. World Health Organization. Statement on the update of WHO’s working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest. Mar 2023 [internet publication].Full text

12. Mallapaty S. Where did Omicron come from? Three key theories. Nature. 2022 Feb;602(7895):26-8.Full text  Abstract

13. World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection. Jun 2022 [internet publication].Full text

14. Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022 Aug 2;378:e070695.Full text  Abstract

15. Adjei S, Hong K, Molinari NM, et al. Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods: United States, April 2020 - June 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1182-9.Full text  Abstract

16. Kozlov M. Omicron's feeble attack on the lungs could make it less dangerous. Nature. 2022 Jan;601(7892):177.Full text  Abstract

17. Hui KPY, Ng KC, Ho JCW, et al. Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract. EBioMedicine. 2022 Sep;83:104232.Full text  Abstract

18. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. May 2024 [internet publication].Full text

19. Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ Open. 2021 Jan 11;11(1):e044640.Full text  Abstract

20. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2021 Feb 1;175(2):143-56.Full text  Abstract

21. World Health Organization. COVID-19 disease in children and adolescents: scientific brief, 29 September 2021. Sep 2021 [internet publication].Full text

22. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr. 2020 Sep 1;174(9):882-9.Full text  Abstract

23. Somekh I, Stein M, Karakis I, et al. Characteristics of SARS-CoV-2 infections in Israeli children during the circulation of different SARS-CoV-2 variants. JAMA Netw Open. 2021 Sep 1;4(9):e2124343.Full text  Abstract

24. Chen F, Tian Y, Zhang L, et al. The role of children in household transmission of COVID-19: a systematic review and meta-analysis. Int J Infect Dis. 2022 May 11;122:266-75.Full text  Abstract

25. Chou R, Dana T, Buckley DI, et al. Epidemiology of and risk factors for coronavirus infection in health care workers: a living rapid review. Ann Intern Med. 2020 Jul 21;173(2):120-36.Full text  Abstract

26. Chou R, Dana T, Buckley DI, et al. Update alert 11: epidemiology of and risk factors for coronavirus infection in health care workers. Ann Intern Med. 2022 Aug;175(8):W83-4.Full text  Abstract

27. Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J (Engl). 2020 May 5;133(9):1015-24.Full text  Abstract

28. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-33.Full text  Abstract

29. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-74.Full text  Abstract

30. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506.Full text  Abstract

31. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-13.Full text  Abstract

32. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199-207.Full text  Abstract

33. Roberts DL, Rossman JS, Jarić I. Dating first cases of COVID-19. PLoS Pathog. 2021 Jun;17(6):e1009620.Full text  Abstract

34. Amendola A, Canuti M, Bianchi S, et al. Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy. Environ Res. 2022 Aug 25;215(Pt 1):113979.Full text  Abstract

35. World Health Organization. WHO-convened global study of the origins of SARS-CoV-2. Nov 2020 [internet publication].Full text

36. Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021 Jan;174(1):69-79.Full text  Abstract

37. World Health Organization. Mask use in the context of COVID-19: interim guidance. Dec 2020 [internet publication].Full text

38. Duval D, Palmer JC, Tudge I, et al. Long distance airborne transmission of SARS-CoV-2: rapid systematic review. BMJ. 2022 Jun 29;377:e068743.Full text  Abstract

39. Birgand G, Peiffer-Smadja N, Fournier S, et al. Assessment of air contamination by SARS-CoV-2 in hospital settings. JAMA Netw Open. 2020 Dec 1;3(12):e2033232.Full text  Abstract

40. Razani N, Malekinejad M, Rutherford GW. Clarification regarding "Outdoor transmission of SARS-CoV-2 and other respiratory viruses: a systematic review". J Infect Dis. 2021 Sep 1;224(5):925-6.Full text  Abstract

41. Francis MR, Gidado S, Nuorti JP. The risk of SARS-CoV-2 transmission in community indoor settings: a systematic review and meta-analysis. J Infect Dis. 2024 May 16 [Epub ahead of print].Full text  Abstract

42. Goldstein KM, Ghadimi K, Mystakelis H, et al. Risk of transmitting coronavirus disease 2019 during nebulizer treatment: a systematic review. J Aerosol Med Pulm Drug Deliv. 2021 Jun;34(3):155-70.Full text  Abstract

43. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. SARS-CoV-2 and the role of fomite transmission: a systematic review. F1000Res. 2021 Mar 24;10:233.Full text  Abstract

44. Onakpoya IJ, Heneghan CJ, Spencer EA, et al. Viral cultures for assessing fomite transmission of SARS-CoV-2: a systematic review and meta-analysis. J Hosp Infect. 2022 Sep 14;130:63-94.Full text  Abstract

45. Trypsteen W, Van Cleemput J, Snippenberg WV, et al. On the whereabouts of SARS-CoV-2 in the human body: a systematic review. PLoS Pathog. 2020 Oct;16(10):e1009037.Full text  Abstract

46. Martinez-Reviejo R, Tejada S, Cipriano A, et al. Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: a systematic review. Anaesth Crit Care Pain Med. 2022 May 6;41(4):101098.Full text  Abstract

47. World Health Organization. Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2: scientific brief. Feb 2021 [internet publication].Full text

48. Jeganathan K, Paul AB. Vertical transmission of SARS-CoV-2: a systematic review. Obstet Med. 2022 Jun;15(2):91-8.Full text  Abstract

49. Zhu F, Zozaya C, Zhou Q, et al. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2021 Sep;106(5):514-21.Full text  Abstract

50. Zhou Q, Gao Y, Wang X, et al. Nosocomial infections among patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):629.Full text  Abstract

51. Centre for Evidence-Based Medicine; Heneghan C, Howdon D, Oke J, et al. The ongoing problem of UK hospital acquired infections. Oct 2020 [internet publication].Full text

52. Read JM, Green CA, Harrison EM, et al. Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave. Lancet. 2021 Sep 18;398(10305):1037-8.Full text  Abstract

53. Rhee C, Baker M, Vaidya V, et al. Incidence of nosocomial COVID-19 in patients hospitalized at a large US academic medical center. JAMA Netw Open. 2020 Sep 1;3(9):e2020498.Full text  Abstract

54. Subramaniam A, Lim ZJ, Ponnapa Reddy M, et al. SARS-CoV-2 transmission risk to healthcare workers performing tracheostomies: a systematic review. ANZ J Surg. 2022 Jul;92(7-8):1614-25.Full text  Abstract

55. Ge Y, Martinez L, Sun S, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19: a population-based cohort study in Zhejiang Province, China. JAMA Intern Med. 2021 Oct 1;181(10):1343-50.Full text  Abstract

56. Hakki S, Zhou J, Jonnerby J, et al. Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study. Lancet Respir Med. 2022 Nov;10(11):1061-73.Full text  Abstract

57. Johnston C, Hughes H, Lingard S, et al. Immunity and infectivity in covid-19. BMJ. 2022 Jul 1;378:e061402.Full text  Abstract

58. Jefferson T, Spencer EA, Brassey J, et al. Transmission of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) from pre and asymptomatic infected individuals: a systematic review. Clin Microbiol Infect. 2022 Feb;28(2):178-89.Full text  Abstract

59. Jefferson T, Spencer EA, Onakpoya IJ, et al. Transmission of SARS-CoV-2 from pre and asymptomatic infected individuals: a systematic review update. Clin Microbiol Infect. 2022 Nov;28(11):1511-2.Full text  Abstract

60. Qiu X, Nergiz AI, Maraolo AE, et al. The role of asymptomatic and pre-symptomatic infection in SARS-CoV-2 transmission: a living systematic review. Clin Microbiol Infect. 2021 Apr;27(4):511-9.Full text  Abstract

61. Zhou J, Singanayagam A, Goonawardane N, et al. Viral emissions into the air and environment after SARS-CoV-2 human challenge: a phase 1, open label, first-in-human study. Lancet Microbe. 2023 Aug;4(8):e579-90.Full text  Abstract

62. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 May;63(5):706-11.Full text  Abstract

63. Luo SH, Liu W, Liu ZJ, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2). Chin Med J (Engl). 2020 May 5;133(9):1123-5.Full text  Abstract

64. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2021 Jan;93(1):518-21.Full text  Abstract

65. Li C, Ji F, Wang L, et al. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020 Mar 31;26(7).Full text  Abstract

66. Liu J, Huang J, Xiang D. Large SARS-CoV-2 outbreak caused by asymptomatic traveler, China. Emerg Infect Dis. 2020 Jun 30;29(9).Full text  Abstract

67. Jiang XL, Zhang XL, Zhao XN, et al. Transmission potential of asymptomatic and paucisymptomatic severe acute respiratory syndrome coronavirus 2 infections: a three-family cluster study in China. 2020 Jun 11;221(12):1948-52.Full text  Abstract

68. Gao M, Yang L, Chen X, et al. A study on infectivity of asymptomatic SARS-CoV-2 carriers. Respir Med. 2020 May 13;169:106026.Full text  Abstract

69. Chen F, Fu D, Yang Q, et al. Low transmission risk of 9 asymptomatic carriers tested positive for both SARS-CoV-2 nucleic acid and serum IgG. J Infect. 2020 Sep;81(3):452-82.Full text  Abstract

70. Danis K, Epaulard O, Bénet T, et al. Cluster of coronavirus disease 2019 (Covid-19) in the French Alps, 2020. Clin Infect Dis. 2020 Jul 28;71(15):825-32.Full text  Abstract

71. Cao S, Gan Y, Wang C, et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China. Nat Commun. 2020 Nov 20;11(1):5917.Full text  Abstract

72. UK Health Security Agency. COVID-19 Omicron variant: infectious period and asymptomatic and symptomatic transmission. ​Jan 2024 [internet publication].Full text

73. Buitrago-Garcia D, Ipekci AM, Heron L, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: update of a living systematic review and meta-analysis. PLoS Med. 2022 May;19(5):e1003987.Full text  Abstract

74. Chen X, Huang Z, Wang J, et al. Ratio of asymptomatic COVID-19 cases among ascertained SARS-CoV-2 infections in different regions and population groups in 2020: a systematic review and meta-analysis including 130 123 infections from 241 studies. BMJ Open. 2021 Dec 7;11(12):e049752.Full text  Abstract

75. Shang W, Kang L, Cao G, et al. Percentage of asymptomatic infections among SARS-CoV-2 Omicron variant-positive individuals: a systematic review and meta-analysis. Vaccines (Basel). 2022 Jun 30;10(7):1049.Full text  Abstract

76. Stubblefield WB, Talbot HK, Feldstein L, et al. Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for patients with COVID-19: Nashville, Tennessee. Clin Infect Dis. 2021 May 4;72(9):1645-8.Full text  Abstract

77. Althouse BM, Wenger EA, Miller JC, et al. Superspreading events in the transmission dynamics of SARS-CoV-2: opportunities for interventions and control. PLoS Biol. 2020 Nov 12;18(11):e3000897.Full text  Abstract

78. Lopez AS, Hill M, Antezano J, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities: Salt Lake City, Utah, April–July 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1319-23.Full text  Abstract

79. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university campus: North Carolina, August 2020. MMWR Morb Mortal Wkly Rep. 2020 Oct 2;69(39):1416-8.Full text  Abstract

80. Xu W, Li X, Dong Y, et al. SARS-CoV-2 transmission in schools: an updated living systematic review (version 2; November 2020). J Glob Health. 2021 Jun 10;11:10004.Full text  Abstract

81. Caini S, Martinoli C, La Vecchia C, et al. SARS-CoV-2 circulation in the school setting: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022 Apr 28;19(9):5384.Full text  Abstract

82. Karki SJ, Joachim A, Heinsohn T, et al. Risk of infection and contribution to transmission of SARS-CoV-2 in school staff: a systematic review. BMJ Open. 2021 Nov 3;11(11):e052690.Full text  Abstract

83. Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet. 2021 Oct 2;398(10307):1217-29.Full text  Abstract

84. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis. 2011 Aug;15(8):e510-3.Full text  Abstract

85. World Health Organization. Clinical management of COVID-19: living guideline, 18 August 2023. Aug 2023 [internet publication].Full text

86. Xin H, Wong JY, Murphy C, et al. The incubation period distribution of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Clin Infect Dis. 2021 Dec 16;73(12):2344-52.Full text  Abstract

87. Li B, Zhang S, Zhang R, et al. Epidemiological and clinical characteristics of COVID-19 in children: a systematic review and meta-analysis. Front Pediatr. 2020 Nov 2;8:591132.Full text  Abstract

88. Wu Y, Kang L, Guo Z, et al. Incubation period of COVID-19 caused by unique SARS-CoV-2 strains: a systematic review and meta-analysis. JAMA Netw Open. 2022 Aug 1;5(8):e2228008.Full text  Abstract

89. Ahammed T, Anjum A, Rahman MM, et al. Estimation of novel coronavirus (COVID-19) reproduction number and case fatality rate: a systematic review and meta-analysis. Health Sci Rep. 2021 Jun;4(2):e274.Full text  Abstract

90. Tian T, Huo X. Secondary attack rates of COVID-19 in diverse contact settings, a meta-analysis. J Infect Dev Ctries. 2020 Dec 31;14(12):1361-7.Full text  Abstract

91. Thompson HA, Mousa A, Dighe A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis. Clin Infect Dis. 2021 Aug 2;73(3):e754-64.Full text  Abstract

92. Madewell ZJ, Yang Y, Longini IM Jr, et al. Factors associated with household transmission of SARS-CoV-2: an updated systematic review and meta-analysis. JAMA Netw Open. 2021 Aug 2;4(8):e2122240.Full text  Abstract

93. Silverberg SL, Zhang BY, Li SNJ, et al. Child transmission of SARS-CoV-2: a systematic review and meta-analysis. BMC Pediatr. 2022 Apr 2;22(1):172.Full text  Abstract

94. Madewell ZJ, Yang Y, Longini IM Jr, et al. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open. 2022 Apr 1;5(4):e229317.Full text  Abstract

95. Kunasekaran M, Quigley A, Rahman B, et al. Factors associated with SARS-CoV-2 attack rates in aged care: a meta-analysis. Open Forum Infect Dis. 2022 Mar;9(3):ofac033.Full text  Abstract

96. Viner R, Waddington C, Mytton O, et al. Transmission of SARS-CoV-2 by children and young people in households and schools: a meta-analysis of population-based and contact-tracing studies. J Infect. 2022 Mar;84(3):361-82.Full text  Abstract

97. Vardavas CI, Nikitara K, Aslanoglou K, et al. Systematic review of outbreaks of COVID-19 within households in the European region when the child is the index case. BMJ Paediatr Open. 2023 Jan;7(1):e001718.Full text  Abstract

98. Jørgensen SB, Nygård K, Kacelnik O, et al. Secondary attack rates for Omicron and Delta variants of SARS-CoV-2 in Norwegian households. JAMA. 2022 Apr 26;327(16):1610-1.Full text  Abstract

99. Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021 May;21(5):629-36.Full text  Abstract

100. Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe. 2021 Jan;2(1):e13-22.Full text  Abstract

101. Li WT, Zhang Y, Liu M, et al. Prolonged viral shedding in feces of children with COVID-19: a systematic review and synthesis of data. Eur J Pediatr. 2022 Dec;181(12):4011-7.Full text  Abstract

102. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 Dec 24;383(26):2586-8.Full text  Abstract

103. Stokel-Walker C. How long does SARS-CoV-2 stay in the body? BMJ. 2022 Jun 28;377:o1555.Full text  Abstract

104. Widders A, Broom A, Broom J. SARS-CoV-2: the viral shedding vs infectivity dilemma. Infect Dis Health. 2020 Aug;25(3):210-5.Full text  Abstract

105. Jung J, Kim JY, Park H, et al. Transmission and infectious SARS-CoV-2 shedding kinetics in vaccinated and unvaccinated individuals. JAMA Netw Open. 2022 May 2;5(5):e2213606.Full text  Abstract

106. Wu Y, Guo Z, Yuan J, et al. Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 Omicron variant in the upper respiratory tract: a systematic review and meta-analysis. Int J Infect Dis. 2023 Apr;129:228-35.Full text  Abstract

107. Menezes RG, Rizwan T, Saad Ali S, et al. Postmortem findings in COVID-19 fatalities: a systematic review of current evidence. Leg Med (Tokyo). 2021 Dec 7;54:102001.Full text  Abstract

108. Lancet Respiratory Medicine. COVID-19: pathophysiology of acute disease. May 2021 [internet publication].Full text

109. Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID-19: a systematic review. PLoS One. 2021;16(4):e0250708.Full text  Abstract

110. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271-80.Full text  Abstract

111. Chen Y, Guo Y, Pan Y, et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40.Full text  Abstract

112. Coutard B, Valle C, de Lamballerie X, et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020 Feb 10;176:104742. Abstract

113. Piplani S, Singh PK, Winkler DA, et al. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021 Jun 24;11(1):13063.Full text  Abstract

114. Lei Y, Zhang J, Schiavon CR, et al. SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE 2. Circ Res. 2021 Apr 30;128(9):1323-6.Full text  Abstract

115. Suzuki YJ, Gychka SG. SARS-CoV-2 spike protein elicits cell signaling in human host cells: implications for possible consequences of COVID-19 vaccines. Vaccines (Basel). 2021 Jan 11;9(1):36.Full text  Abstract

116. Ramanathan M, Ferguson ID, Miao W, et al. SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity. Lancet Infect Dis. 2021 Aug;21(8):1070.Full text  Abstract

117. Raviraj KG, Shobhana SS. Findings and inferences from full autopsies, minimally invasive autopsies and biopsy studies in patients who died as a result of COVID19: a systematic review. Forensic Sci Med Pathol. 2022 Sep;18(3):369-81.Full text  Abstract

118. Sofizan NMFBN, Rahman AFBA, Soon LP, et al. Autopsy findings in COVID-19 infection-related death: a systematic review. Egypt J Forensic Sci. 2022;12(1):22.Full text  Abstract

119. Osuchowski MF, Winkler MS, Skirecki T, et al. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021 Jun;9(6):622-42.Full text  Abstract

120. Milross L, Majo J, Cooper N, et al. Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. Lancet Respir Med. 2021 Dec 3;10(1):95-106.Full text  Abstract

121. Ackermann M, Kamp JC, Werlein C, et al. The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodelling. EBioMedicine. 2022 Nov;85:104296.Full text  Abstract

122. Stenton S, McPartland J, Shukla R, et al. SARS-COV2 placentitis and pregnancy outcome: a multicentre experience during the Alpha and early Delta waves of coronavirus pandemic in England. EClinicalMedicine. 2022 May;47:101389.Full text  Abstract

123. Dieter C, Brondani LA, Leitão CB, et al. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: a systematic review and meta-analysis. PLoS One. 2022 Jul 6;17(7):e0270627.Full text  Abstract

124. Pecoraro V, Cuccorese M, Trenti T. Genetic polymorphisms of ACE1, ACE2, IFTM3, TMPRSS2 and TNFα genes associated with susceptibility and severity of SARS-CoV-2 infection: a systematic review and meta-analysis. Clin Exp Med. 2023 Nov;23(7):3251-64.Full text  Abstract

125. World Health Organization. Public health surveillance for COVID-19: interim guidance. Jul 2022 (addendum Aug 2023) [internet publication].Full text

126. Romero Starke K, Reissig D, Petereit-Haack G, et al. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health. 2021 Dec;6(12):e006434.Full text  Abstract

127. Centers for Disease Control and Prevention. Underlying medical conditions associated with high risk for severe COVID-19: information for healthcare professionals. Apr 2024 [internet publication].Full text

128. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020 Sep;20(9):1034-42.Full text  Abstract

129. Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of age on mortality in patients with COVID-19: a meta-analysis with 611,583 subjects. J Am Med Dir Assoc. 2020 Jul;21(7):915-8.Full text  Abstract

130. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19): United States, February 12 - March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-6.Full text  Abstract

131. Damayanthi HDWT, Prabani KIP. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: a systematic review. Arch Gerontol Geriatr. 2021 Mar 31;95:104411.Full text  Abstract

132. Pijls BG, Jolani S, Atherley A, et al. Temporal trends of sex differences for COVID-19 infection, hospitalisation, severe disease, intensive care unit (ICU) admission and death: a meta-analysis of 229 studies covering over 10M patients. F1000Res. 2022 Jan 5;11:5.Full text  Abstract

133. Twitchell DK, Christensen MB, Hackett G, et al. Examining male predominance of severe COVID-19 outcomes: a systematic review. Androg Clin Res Ther. 2022;3(1):41-53.Full text  Abstract

134. Sze S, Pan D, Nevill CR, et al. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2020 Dec;29:100630.Full text  Abstract

135. Mackey K, Ayers CK, Kondo KK, et al. Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med. 2021 Mar;174(3):362-73.Full text  Abstract

136. Khanijahani A, Iezadi S, Gholipour K, et al. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health. 2021 Nov 24;20(1):248.Full text  Abstract

137. Irizar P, Pan D, Kapadia D, et al. Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: a global systematic review and meta-analysis of over 200 million study participants. EClinicalMedicine. 2023 Mar;57:101877.Full text  Abstract

138. Mathur R, Rentsch CT, Morton CE, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet. 2021 May 8;397(10286):1711-24.Full text  Abstract

139. Siddiq S, Ahmed S, Akram I. Clinical outcomes following COVID-19 infection in ethnic minority groups in the UK: a systematic review and meta-analysis. Public Health. 2023 Sep;222:205-14.Full text  Abstract

140. Urdiales T, Dernie F, Català M, et al. Association between ethnic background and COVID-19 morbidity, mortality and vaccination in England: a multistate cohort analysis using the UK Biobank. BMJ Open. 2023 Sep 21;13(9):e074367.Full text  Abstract

141. Saatci D, Ranger TA, Garriga C, et al. Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr. 2021 Sep 1;175(9):928-38.Full text  Abstract

142. Acosta AM, Garg S, Pham H, et al. Racial and ethnic disparities in rates of COVID-19–associated hospitalization, intensive care unit admission, and in-hospital death in the United States from March 2020 to February 2021. JAMA Netw Open. 2021 Oct 1;4(10):e2130479.Full text  Abstract

143. Magesh S, John D, Li WT, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021 Nov 1;4(11):e2134147.Full text  Abstract

144. Agyemang C, Richters A, Jolani S, et al. Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis. BMJ Glob Health. 2021 Nov;6(11):e007433.Full text  Abstract

145. Raharja A, Tamara A, Kok LT. Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis. J Racial Ethn Health Disparities. 2021 Sep 1;175(9):928-38.Full text  Abstract

146. McMichael TM, Clark S, Pogosjans S, et al. COVID-19 in a long-term care facility: King County, Washington, February 27 – March 9, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):339-42.Full text  Abstract

147. Burki T. England and Wales see 20 000 excess deaths in care homes. Lancet. 2020 May 23;395(10237):1602.Full text  Abstract

148. Graham N, Junghans C, Downes R, et al. SARS-CoV-2 infection, clinical features and outcome of COVID-19 in United Kingdom nursing homes. J Infect. 2020 Sep;81(3):411-9.Full text  Abstract

149. Panagiotou OA, Kosar CM, White EM, et al. Risk factors associated with all-cause 30-day mortality in nursing home residents with COVID-19. JAMA Intern Med. 2021 Apr 1;181(4):439-48.Full text  Abstract

150. Liu H, Chen S, Liu M, et al. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis. 2020 May 9;11(3):668-78.Full text  Abstract

151. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study. BMJ. 2020 May 22;369:m1985.Full text  Abstract

152. Norris T, Razieh C, Zaccardi F, et al. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart. 2022 Jul 13;108(15):1200-8.Full text  Abstract

153. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020 – March 2021. Prev Chronic Dis. 2021 Jul 1;18:E66.Full text  Abstract

154. Adams ML, Katz DL, Grandpre J. Updated estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020 Jul 3;26(9).Full text  Abstract

155. Adams SH, Park MJ, Schaub JP, et al. Medical vulnerability of young adults to severe COVID-19 illness: data from the National Health Interview Survey. J Adolesc Health. 2020 Jul 9;67(3):362-8.Full text  Abstract

156. Ng WH, Tipih T, Makoah NA, et al. Comorbidities in SARS-CoV-2 patients: a systematic review and meta-analysis. mBio. 2021 Feb 9;12(1):e03647-20.Full text  Abstract

157. Zuin M, Rigatelli G, Bilato C, et al. Prognostic role of metabolic syndrome in COVID-19 patients: a systematic review meta-analysis. Viruses. 2021 Sep 27;13(10):1938.Full text  Abstract

158. Choi JH, Choi SH, Yun KW. Risk factors for severe COVID-19 in children: a systematic review and meta-analysis. J Korean Med Sci. 2022 Feb 7;37(5):e35.Full text  Abstract

159. Tadayon Najafabadi B, Rayner DG, Shokraee K, et al. Obesity as an independent risk factor for COVID-19 severity and mortality. Cochrane Database Syst Rev. 2023 May 24;5(5):CD015201.Full text  Abstract

160. Qadar SMZ, Naz H, Shamim S, et al. Prevalence of obesity and its effects in patients with COVID-19: a systematic review and meta-analysis. Hosp Pharm. 2024 Jun;59(3):341-8. Abstract

161. World Obesity Federation. COVID-19 and obesity: the 2021 atlas. Mar 2021 [internet publication].Full text

162. Cai Z, Yang Y, Zhang J. Obesity is associated with severe disease and mortality in patients with coronavirus disease 2019 (COVID-19): a meta-analysis. BMC Public Health. 2021 Aug 4;21(1):1505.Full text  Abstract

163. Sawadogo W, Tsegaye M, Gizaw A, et al. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ Nutr Prev Health. 2022 Jan 19;5(1):10-18.Full text  Abstract

164. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 Jun;9(6):350-9.Full text  Abstract

165. Kompaniyets L, Goodman AB, Belay B, et al. Body mass index and risk for COVID-19–related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death: United States, March – December 2020. MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-61.Full text  Abstract

166. Xu J, Xiao W, Liang X, et al. A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity. BMC Public Health. 2021 Aug 11;21(1):1533.Full text  Abstract

167. Ehwerhemuepha L, Roth B, Patel AK, et al. Association of congenital and acquired cardiovascular conditions with COVID-19 severity among pediatric patients in the US. JAMA Netw Open. 2022 May 2;5(5):e2211967.Full text  Abstract

168. Hessami A, Shamshirian A, Heydari K, et al. Cardiovascular diseases burden in COVID-19: systematic review and meta-analysis. Am J Emerg Med. 2021 Aug;46:382-91.Full text  Abstract

169. Zuin M, Rigatelli G, Bilato C, et al. Pre-existing atrial fibrillation is associated with increased mortality in COVID-19 Patients. J Interv Card Electrophysiol. 2021 Nov;62(2):231-8.Full text  Abstract

170. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: a systematic review and meta-analysis. Cardiol J. 2022;29(1):33-43. Abstract

171. Liang C, Zhang W, Li S, et al. Coronary heart disease and COVID-19: a meta-analysis. Med Clin (Engl Ed). 2021 Jun 11;156(11):547-54.Full text  Abstract

172. Li Y, Pei H, Zhou C, et al. Myocardial injury predicts risk of short-term all-cause mortality in patients with COVID-19: a dose-response meta-analysis. Front Cardiovasc Med. 2022 May 2;9:850447.Full text  Abstract

173. Zuin M, Rigatelli G, Bilato MJ, et al. Prevalence of pre-existing peripheral artery disease in COVID-19 patients and relative mortality risk: systematic review and meta-analysis. Vascular. 2023 Dec;31(6):1103-9.Full text  Abstract

174. Bae S, Kim SR, Kim MN, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373-80.Full text  Abstract

175. Pellicori P, Doolub G, Wong CM, et al. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies. Cochrane Database Syst Rev. 2021 Mar 11;(3):CD013879.Full text  Abstract

176. Hartmann-Boyce J, Rees K, Perring JC, et al. Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care. 2021 Dec;44(12):2790-811.Full text  Abstract

177. Hartmann-Boyce J, Rees K, Onakpoya I, et al. An update to the overview of reviews: risks of and from SARS-COV-2 infection and COVID-19 in people with diabetes. Diabetes Care. 2023 Dec 1;46(12):e215-6.Full text  Abstract

178. Kastora S, Patel M, Carter B, et al. Impact of diabetes on COVID-19 mortality and hospital outcomes from a global perspective: an umbrella systematic review and meta-analysis. Endocrinol Diabetes Metab. 2022 Apr 20:e338.Full text  Abstract

179. Chen Y, Yang D, Cheng B, et al. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care. 2020 Jul;43(7):1399-407.Full text  Abstract

180. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-33.Full text  Abstract

181. Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020 Aug 18;14(6):1563-9.Full text  Abstract

182. Papadopoulos VP, Koutroulos MV, Zikoudi DG, et al. Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis. Diabetol Int. 2021 Mar 23;1-15.Full text  Abstract

183. Prattichizzo F, de Candia P, Nicolucci A, et al. Impact of pre-infection HbA1c levels on COVID-19 prognosis: systematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20:e3476.Full text  Abstract

184. Heidarpour M, Abhari AP, Sadeghpour N, et al. Prediabetes and COVID-19 severity, an underestimated risk factor: a systematic review and meta-analysis. Diabetes Metab Syndr. 2021 Oct 9;15(6):102307.Full text  Abstract

185. Boden I, Bernabeu MO, Dhillon B, et al. Pre-existing diabetic retinopathy as a prognostic factor for COVID-19 outcomes amongst people with diabetes: a systematic review. Diabetes Res Clin Pract. 2022 Apr 5;187:109869.Full text  Abstract

186. Chander S, Deepak V, Kumari R, et al. Glycemic control in critically ill COVID-19 patients: systematic review and meta-analysis. J Clin Med. 2023 Mar 28;12(7):2555.Full text  Abstract

187. Nguyen NN, Ho DS, Nguyen HS, et al. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism. 2022 Mar 31:155196.Full text  Abstract

188. Zhu Z, Zeng Q, Liu Q, et al. Association of glucose-lowering drugs with outcomes in patients with diabetes before hospitalization for COVID-19: a systematic review and network meta-analysis. JAMA Netw Open. 2022 Dec 1;5(12):e2244652.Full text  Abstract

189. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020 Sep;8(9):782-92.Full text  Abstract

190. Yin Y, Rohli KE, Shen P, et al. The epidemiology, pathophysiological mechanisms, and management toward COVID-19 patients with type 2 diabetes: a systematic review. Prim Care Diabetes. 2021 Sep 6;15(6):899-909.Full text  Abstract

191. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020 May;8(5):436-8.Full text  Abstract

192. Centre for Evidence-Based Medicine; Hartmann-Boyce J, Otunla A, Drake J, et al. Asthma and COVID-19: risks and management considerations. May 2020 [internet publication].Full text

193. Gerayeli FV, Milne S, Cheung C, et al. COPD and the risk of poor outcomes in COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Mar;33:100789.Full text  Abstract

194. Finnerty JP, Hussain ABMA, Ponnuswamy A, et al. Asthma and COPD as co-morbidities in patients hospitalised with Covid-19 disease: a global systematic review and meta-analysis. BMC Pulm Med. 2023 Nov 22;23(1):462.Full text  Abstract

195. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):699-711.Full text  Abstract

196. Otunla A, Rees K, Dennison P, et al. Risks of infection, hospital and ICU admission, and death from COVID-19 in people with asthma: systematic review and meta-analyses. BMJ Evid Based Med. 2022 Oct;27(5):263-73.Full text  Abstract

197. World Health Organization. Asthma and COVID-19: scientific brief, 19 April 2021. Apr 2021 [internet publication].Full text

198. Sallih ASM, Wee MW, Zaki RA, et al. The outcome of COVID-19 in children with chronic lung disease: systematic review and meta-analyses. Pediatr Pulmonol. 2023 Jun;58(6):1784-97. Abstract

199. Hariyanto TI, Kurniawan A. Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Sleep Med. 2021 Apr 1;82:47-53.Full text  Abstract

200. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID-19. BMJ Open Respir Res. 2021 Jan;8(1):e000845.Full text  Abstract

201. Mathew HR, Choi MY, Parkins MD, et al. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173.Full text  Abstract

202. Terlizzi V, Motisi MA, Pellegrino R, et al. Risk factors for severe COVID-19 in people with cystic fibrosis: a systematic review. Front Pediatr. 2022 Aug 8;10:958658.Full text  Abstract

203. Wang Y, Feng R, Xu J, et al. An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021 Oct;93(10):5682-6.Full text  Abstract

204. Aggarwal AN, Agarwal R, Dhooria S, et al. Active pulmonary tuberculosis and coronavirus disease 2019: a systematic review and meta-analysis. PLoS One. 2021;16(10):e0259006.Full text  Abstract

205. Ouyang L, Gong J, Yu M. Pre-existing interstitial lung disease in patients with coronavirus disease 2019: a meta-analysis. Int Immunopharmacol. 2021 Sep 9;100:108145.Full text  Abstract

206. Wang Y, Hao Y, Hu M, et al. Interstitial lung disease independently associated with higher risk for COVID-19 severity and mortality: a meta-analysis of adjusted effect estimates. Int Immunopharmacol. 2022 Oct;111:109088.Full text  Abstract

207. Lin YC, Lai TS, Lin SL, et al. Outcomes of coronavirus 2019 infection in patients with chronic kidney disease: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2021;12:2040622321998860.Full text  Abstract

208. Chung EY, Palmer SC, Natale P, et al. Incidence and outcomes of COVID-19 in people with CKD: a systematic review and meta-analysis. Am J Kidney Dis. 2021 Dec;78(6):804-15.Full text  Abstract

209. Nopsopon T, Kittrakulrat J, Takkavatakarn K, et al. Covid-19 in end-stage renal disease patients with renal replacement therapies: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jun 15;15(6):e0009156.Full text  Abstract

210. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020 Jul 10;:1-9.Full text  Abstract

211. Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):612-20.Full text  Abstract

212. Liu M, Mei K, Tan Z, et al. Liver fibrosis scores and hospitalization, mechanical ventilation, severity, and death in patients with COVID-19: a systematic review and dose-response meta-analysis. Can J Gastroenterol Hepatol. 2022 Mar 29;2022:7235860.Full text  Abstract

213. Middleton P, Hsu C, Lythgoe MP. Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. BMJ Open Gastroenterol. 2021 Oct;8(1):e000739.Full text  Abstract

214. Wei B, Liu Y, Li H, et al. Impact of alcohol consumption on coronavirus disease 2019 severity: a systematic review and meta-analysis. J Med Virol. 2023 Feb;95(2):e28547. Abstract

215. Tao Z, Li Y, Cheng B, et al. Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis. J Clin Gastroenterol. 2021 Nov-Dec 01;55(10):830-5.Full text  Abstract

216. Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 Aug;69(8):1545-7.Full text  Abstract

217. Zhou YJ, Zheng KI, Wang XB, et al. Younger patients with MAFLD are at increased risk of severe COVID-19 illness: a multicenter preliminary analysis. J Hepatol. 2020 Sep;73(3):719-21.Full text  Abstract

218. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2020 Sep 1;370:m3320.Full text  Abstract

219. Allotey J, Stallings E, Bonet M, et al. Update to living systematic review on covid-19 in pregnancy. BMJ. 2022 May 30;377:o1205.Full text  Abstract

220. Khalil A, Kalafat E, Benlioglu C, et al. SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis of clinical features and pregnancy outcomes. EClinicalMedicine. 2020 Aug;25:100446.Full text  Abstract

221. Zambrano LD, Ellington S, Strid P, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22–October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 Nov 6;69(44):1641-7.Full text  Abstract

222. Vousden N, Ramakrishnan R, Bunch K, et al. Management and implications of severe COVID-19 in pregnancy in the UK: data from the UK Obstetric Surveillance System national cohort. Acta Obstet Gynecol Scand. 2022 Apr;101(4):461-70.Full text  Abstract

223. Smith ER, Oakley E, Grandner GW, et al. Clinical risk factors of adverse outcomes among women with COVID-19 in the pregnancy and postpartum period: a sequential, prospective meta-analysis. Am J Obstet Gynecol. 2023 Feb;228(2):161-77.Full text  Abstract

224. Patanavanich R, Glantz SA. Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis. BMC Public Health. 2021 Aug 16;21(1):1554.Full text  Abstract

225. Gallus S, Scala M, Possenti I, et al. The role of smoking in COVID-19 progression: a comprehensive meta-analysis. Eur Respir Rev. 2023 Mar 31;32(167):220191.Full text  Abstract

226. Cai G, Bossé Y, Xiao F, et al. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1557-9.Full text  Abstract

227. Patanavanich R, Siripoon T, Amponnavarat S, et al. Active smokers are at higher risk of COVID-19 death: a systematic review and meta-analysis. Nicotine Tob Res. 2023 Jan 5;25(2):177-84.Full text  Abstract

228. World Health Organization. Smoking and COVID-19: scientific brief. Jun 2020 [internet publication].Full text

229. Yu J Ouyang W, Chua ML, et al. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. 2020 Mar 25;6(7):1108-10.Full text  Abstract

230. Arayici ME, Kipcak N, Kayacik U, et al. Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients. J Cancer Res Clin Oncol. 2022 Jul 13;1-14.Full text  Abstract

231. Naimi A, Yashmi I, Jebeleh R, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: a systematic review and meta-analysis. J Clin Lab Anal. 2022 Apr 6:e24387.Full text  Abstract

232. Zarifkar P, Kamath A, Robinson C, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e180-91.Full text  Abstract

233. Nadkarni AR, Vijayakumaran SC, Gupta S, et al. Mortality in cancer patients with COVID-19 who are admitted to an ICU or who have severe COVID-19: a systematic review and meta-analysis. JCO Glob Oncol. 2021 Aug;7:1286-305.Full text  Abstract

234. Kaur H, Thakur JS, Paika R, et al. Impact of underlying comorbidities on mortality in SARS-COV-2 infected cancer patients: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2021 May 1;22(5):1333-49.Full text  Abstract

235. Chavez-MacGregor M, Lei X, Zhao H, et al. Evaluation of COVID-19 mortality and adverse outcomes in US patients with or without cancer. JAMA Oncol. 2022 Jan 1;8(1):69-78.Full text  Abstract

236. Ruiz JI, Lopez-Olivo MA, Geng Y, et al. COVID-19 outcomes in patients with cancer receiving immune checkpoint inhibitors: a systematic review. J Immunother Precis Oncol. 2023 May;6(2):103-10.Full text  Abstract

237. Boulad F, Kamboj M, Bouvier N, et al. COVID-19 in children with cancer in New York City. JAMA Oncol. 2020 Sep 1;6(9):1459-60.Full text  Abstract

238. Mukkada S, Bhakta N, Chantada GL, et al. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. Lancet Oncol. 2021 Oct;22(10):1416-26.Full text  Abstract

239. Dorantes-Acosta E, Ávila-Montiel D, Klünder-Klünder M, et al. Survival and complications in pediatric patients with cancer and COVID-19: a meta-analysis. Front Oncol. 2020 Jan 21;10:608282.Full text  Abstract

240. Schlage S, Lehrnbecher T, Berner R, et al. SARS-CoV-2 in pediatric cancer: a systematic review. Eur J Pediatr. 2022 Apr;181(4):1413-27.Full text  Abstract

241. Xu J, Xiao W, Liang X, et al. The association of cerebrovascular disease with adverse outcomes in COVID-19 patients: a meta-analysis based on adjusted effect estimates. J Stroke Cerebrovasc Dis. 2020 Nov;29(11):105283.Full text  Abstract

242. Patel U, Malik P, Shah D, et al. Pre-existing cerebrovascular disease and poor outcomes of COVID-19 hospitalized patients: a meta-analysis. J Neurol. 2021 Jan;268(1):240-7.Full text  Abstract

243. Huang H, Chen J, Fang S, et al. Association between previous stroke and severe COVID-19: a retrospective cohort study and an overall review of meta-analysis. Front Neurol. 2022 Jul 12;13:922936.Full text  Abstract

244. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Nov 1;78(11):1208-17.Full text  Abstract

245. Ceban F, Nogo D, Carvalho IP, et al. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021 Oct 1;78(10):1079-91.Full text  Abstract

246. Pardamean E, Roan W, Iskandar KTA, et al. Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry. 2022 Feb 4;75:61-7.Full text  Abstract

247. Gatti M, Rinaldi M, Bussini L, et al. Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis. Clin Microbiol Infect. 2022 Aug;28(8):1057-65.Full text  Abstract

248. Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022 Jan 14:e13792.Full text  Abstract

249. Clift AK, Coupland CAC, Keogh RH, et al. COVID-19 mortality risk in Down syndrome: results from a cohort study of 8 million adults. Ann Intern Med. 2021 Apr;174(4):572-6.Full text  Abstract

250. Pitchan Velammal PNK, Balasubramanian S, Ayoobkhan FS, et al. COVID-19 in patients with Down syndrome: a systematic review. Immun Inflamm Dis. 2024 Mar;12(3):e1219.Full text  Abstract

251. Williamson EJ, McDonald HI, Bhaskaran K, et al. Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform. BMJ. 2021 Jul 14;374:n1592.Full text  Abstract

252. Bosworth ML, Ayoubkhani D, Nafilyan V, et al. Deaths involving COVID-19 by self-reported disability status during the first two waves of the COVID-19 pandemic in England: a retrospective, population-based cohort study. Lancet Public Health. 2021 Nov;6(11):e817-25.Full text  Abstract

253. Hariyanto TI, Putri C, Arisa J, et al. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2020 Nov 19;93:104299.Full text  Abstract

254. Saragih ID, Saragih IS, Batubara SO, et al. Dementia as a mortality predictor among older adults with COVID-19: a systematic review and meta-analysis of observational study. Geriatr Nurs. 2021 Sep-Oct;42(5):1230-9.Full text  Abstract

255. Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in June 2020. Jul 2020 [internet publication].Full text

256. Wang Q, Davis PB, Gurney ME, et al. COVID-19 and dementia: analyses of risk, disparity, and outcomes from electronic health records in the US. Alzheimers Dement. 2021 Aug;17(8):1297-306.Full text  Abstract

257. Singson JRC, Kirley PD, Pham H, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19: COVID-NET, 10 States, March 2020 - February 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 8;71(27):878-84.Full text  Abstract

258. Fagni F, Simon D, Tascilar K, et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021 Oct;3(10):e724-36.Full text  Abstract

259. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66.Full text  Abstract

260. Nørgård BM, Nielsen J, Knudsen T, et al. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: a Danish cohort study. Br J Clin Pharmacol. 2021 Apr;87(4):2111-20.Full text  Abstract

261. Tassone D, Thompson A, Connell W, et al. Immunosuppression as a risk factor for COVID-19: a meta-analysis. Intern Med J. 2021 Feb;51(2):199-205.Full text  Abstract

262. Bhaskaran K, Rentsch CT, MacKenna B, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. 2021 Jan;8(1):e24-32.Full text  Abstract

263. Tesoriero JM, Swain CE, Pierce JL, et al. COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State. JAMA Netw Open. 2021 Feb 1;4(2):e2037069.Full text  Abstract

264. Chanda D, Minchella PA, Kampamba D, et al. COVID-19 severity and COVID-19-associated deaths among hospitalized patients with HIV infection: Zambia, March-December 2020. MMWR Morb Mortal Wkly Rep. 2021 Jun 4;70(22):807-10.Full text  Abstract

265. Yang X, Sun J, Patel RC, et al. Associations between HIV infection and clinical spectrum of COVID-19: a population level analysis based on US National COVID Cohort Collaborative (N3C) data. Lancet HIV. 2021 Nov;8(11):e690-700.Full text  Abstract

266. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence. Immun Inflamm Dis. 2021 Dec;9(4):1160-85.Full text  Abstract

267. Hanson HA, Kim E, Badowski ME. A systematic review: impact of SARS-CoV-2 infection on morbidity, mortality, and viral suppression in patients living with HIV. SN Compr Clin Med. 2023;5(1):144.Full text  Abstract

268. World Health Organization. Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection. Jul 2021 [internet publication].Full text

269. Bertagnolio S, Thwin SS, Silva R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022 Jul;9(7):e486-95.Full text  Abstract

270. Wang H, Jonas KJ. The likelihood of severe COVID-19 outcomes among PLHIV with various comorbidities: a comparative frequentist and Bayesian meta-analysis approach. J Int AIDS Soc. 2021 Nov;24(11):e25841.Full text  Abstract

271. Rahmati M, Shamsi MM, Khoramipour K, et al. Baseline physical activity is associated with reduced mortality and disease outcomes in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2022 Apr 13:e2349.Full text  Abstract

272. Centers for Disease Control and Prevention. Brief summary of findings on the association between physical inactivity and severe COVID-19 outcomes. 2022 [internet publication].Full text

273. Ezzatvar Y, Ramírez-Vélez R, Izquierdo M, et al. Physical activity and risk of infection, severity and mortality of COVID-19: a systematic review and non-linear dose-response meta-analysis of data from 1 853 610 adults. Br J Sports Med. 2022 Aug 22 [Epub ahead of print].Full text  Abstract

274. Rejeki PS, Witarto BS, Witarto AP, et al. Importance of moderate-to-vigorous physical activity during the COVID-19 pandemic: a systematic review and meta-analysis. J Basic Clin Physiol Pharmacol. 2023 Mar 24;34(3):311-20. Abstract

275. Michelon I, Vilbert M, Pinheiro IS, et al. COVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis. EClinicalMedicine. 2023 Dec;66:102330.Full text  Abstract

276. Lee JX, Chieng WK, Lau SCD, et al. COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med (Lausanne). 2021 Oct 13;8:757510.Full text  Abstract

277. Silva Borborema T, Moreira Brito JC, Lima Batista EM, et al. Case fatality rate and severity of COVID-19 among patients with sickle cell disease: a systematic review and meta-analysis. Hemoglobin. 2023 Nov;47(2):85-96. Abstract

278. Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021 Oct;174(10):1483-7.Full text  Abstract

279. Panepinto JA, Brandow A, Mucalo L, et al. Coronavirus disease among persons with sickle cell disease, United States, March 20 – May 21, 2020. Emerg Infect Dis. 2020 Jul 8;26(10).Full text  Abstract

280. Hussain FA, Njoku FU, Saraf SL, et al. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-2.Full text  Abstract

281. Nur E, Gaartman AE, van Tuijn CFJ, et al. Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Am J Hematol. 2020 Jun;95(6):725-6.Full text  Abstract

282. World Health Organization. Hypertension and COVID-19. Jun 2021 [internet publication].Full text

283. Qian Z, Li Z, Peng J, et al. Association between hypertension and prognosis of patients with COVID-19: a systematic review and meta-analysis. Clin Exp Hypertens. 2022 May 8:1-8. Abstract

284. Pranata R, Lim MA, Huang I, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regression. J Renin Angiotensin Aldosterone Syst. 2020 Apr-Jun;21(2):1470320320926899.Full text  Abstract

285. Kabia AU, Li P, Jin Z, et al. The effects of hypertension on the prognosis of coronavirus disease 2019: a systematic review and meta-analysis on the interactions with age and antihypertensive treatment. J Hypertens. 2022 Dec 1;40(12):2323-36.Full text  Abstract

286. de Almeida-Pititto B, Dualib PM, Zajdenverg L, et al. Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis. Diabetol Metab Syndr. 2020 Aug 31;12:75.Full text  Abstract

287. Du Y, Zhou N, Zha W, et al. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: a meta-analysis. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):745-55.Full text  Abstract

288. Goldstein MR, Poland GA, Graeber CW. Are certain drugs associated with enhanced mortality in COVID-19? QJM. 2020 Jul 1;113(7):509-10.Full text  Abstract

289. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med. 2020 Aug 4;173(3):195-203.Full text  Abstract

290. Mackey K, Kansagara D, Vela K. Update alert 10: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2023 May;176(5):eL230049.Full text  Abstract

291. Baillargeon J, Polychronopoulou E, Kuo YF, et al. The impact of substance use disorder on COVID-19 outcomes. Psychiatr Serv. 2021 May 1;72(5):578-81.Full text  Abstract

292. Allen B, El Shahawy O, Rogers ES, et al. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2021 Sep 22;43(3):462-5.Full text  Abstract

293. Behnoush AH, Bazmi E, Forouzesh M, et al. Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis. Addict Sci Clin Pract. 2022 Nov 30;17(1):68.Full text  Abstract

294. Aparicio C, Willis ZI, Nakamura MM, et al. Risk factors for pediatric critical COVID-19: a systematic review and meta-analysis. J Pediatric Infect Dis Soc. 2024 May 23 [Epub ahead of print]. Abstract

295. Kompaniyets L, Agathis NT, Nelson JM, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021 Jun 1;4(6):e2111182.Full text  Abstract

296. Akbar MR, Wibowo A, Pranata R, et al. Low serum 25-hydroxyvitamin d (vitamin d) level is associated with susceptibility to COVID-19, severity, and mortality: a systematic review and meta-analysis. Front Nutr. 2021 Mar 29;8:660420.Full text  Abstract

297. Crafa A, Cannarella R, Condorelli RA, et al. Influence of 25-hydroxy-cholecalciferol levels on SARS-CoV-2 infection and COVID-19 severity: a systematic review and meta-analysis. EClinicalMedicine. 2021 Jul;37:100967.Full text  Abstract

298. Szarpak L, Rafique Z, Gasecka A, et al. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19. Cardiol J. 2021;28(5):647-54.Full text  Abstract

299. Shah K, V P V, Pandya A, et al. Low vitamin D levels and prognosis in a COVID-19 pediatric population: a systematic review. QJM. 2021 Nov 5;114(7):447-53.Full text  Abstract

300. Borsche L, Glauner B, von Mendel J. COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/mL 25(OH)D3: results of a systematic review and meta-analysis. Nutrients. 2021 Oct 14;13(10):3596.Full text  Abstract

301. Ebrahimzadeh A, Mohseni S, Narimani B, et al. Association between vitamin D status and risk of covid-19 in-hospital mortality: a systematic review and meta-analysis of observational studies. Crit Rev Food Sci Nutr. 2021 Dec 9:1-11. Abstract

302. Dissanayake HA, de Silva NL, Sumanatilleke M, et al. Prognostic and therapeutic role of vitamin D in COVID-19: systematic review and meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1484-502.Full text  Abstract

303. Bassatne A, Basbous M, Chakhtoura M, et al. The link between COVID-19 and vitamin D (VIVID): a systematic review and meta-analysis. Metabolism. 2021 Mar 24:154753.Full text  Abstract

304. Grove A, Osokogu O, Al-Khudairy L, et al. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review. BMJ Open. 2021 May 28;11(5):e043737.Full text  Abstract

305. Bignardi PR, de Andrade Castello P, de Matos Aquino B, et al. Is the vitamin D status of patients with COVID-19 associated with reduced mortality? A systematic review and meta-analysis. Arch Endocrinol Metab. 2023 Mar 10;67(2):276-88.Full text  Abstract

306. Chen J, Mei K, Xie L, et al. Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. Nutr J. 2021 Oct 31;20(1):89.Full text  Abstract

307. Fatima K, Almas T, Lakhani S, et al. The use of proton pump inhibitors and COVID-19: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Feb 28;7(3):37.Full text  Abstract

308. Li GF, An XX, Yu Y, et al. Do proton pump inhibitors influence SARS-CoV-2 related outcomes? A meta-analysis. Gut. 2021 Sep;70(9):1806-8.Full text  Abstract

309. Einarsdottir MJ, Kibiwott Kirui B, Li H, et al. Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort. BMJ Open. 2024 Mar 15;14(3):e080640.Full text  Abstract

310. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021 Mar;80(3):384-91.Full text  Abstract

311. Conway R, Grimshaw AA, Konig MF, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: a systematic literature review and meta-analysis. Arthritis Rheumatol. 2022 May;74(5):766-75.Full text  Abstract

312. Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021 Oct 1;4(10):e2129639.Full text  Abstract

313. Andersen KM, Bates BA, Rashidi ES, et al. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatol. 2022 Jan;4(1):e33-41.Full text  Abstract

314. Tripathi K, Godoy Brewer G, Thu Nguyen M, et al. COVID-19 and outcomes in patients with inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2022 Aug 1;28(8):1265-79.Full text  Abstract

315. Batsiou A, Mantzios P, Piovani D, et al. SARS-CoV-2 infection and outcomes in children with inflammatory bowel diseases: a systematic review. J Clin Med. 2022 Dec 6;11(23):7238.Full text  Abstract

316. Lee MH, Li HJ, Wasuwanich P, et al. COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: an updated systematic review and meta-analysis. Rev Med Virol. 2023 Mar;33(2):e2414.Full text  Abstract

317. Alrashed F, Battat R, Abdullah I, et al. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2021 Oct;8(1):e000774.Full text  Abstract

318. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 Jul;69(7):1213-7.Full text  Abstract

319. Singh S, Khan A, Chowdhry M, et al. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the united states: a multicenter research network study. Gastroenterology. 2020 Oct;159(4):1575-8.Full text  Abstract

320. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021 Apr;70(4):725-32.Full text  Abstract

321. Singh AK, Jena A, Kumar-M P, et al. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021 Mar;9(2):159-76.Full text  Abstract

322. Sperger J, Shah KS, Lu M, et al. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open. 2021 Nov 12;11(11):e049740.Full text  Abstract

323. Sakthiswary R, Chuah HY, Chiang KS, et al. COVID-19 in systemic lupus erythematosus: a pooled analysis and systematic review of case reports and series. Lupus. 2021 Oct;30(12):1946-54.Full text  Abstract

324. Rutherford MA, Scott J, Karabayas M, et al. Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: a binational, registry-based cohort study. Arthritis Rheumatol. 2021 Sep;73(9):1713-9.Full text  Abstract

325. Sattui SE, Conway R, Putman MS, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021 Dec;3(12):e855-64.Full text  Abstract

326. Louapre C, Collongues N, Stankoff B, et al. Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88.Full text  Abstract

327. Salter A, Fox RJ, Newsome SD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neurol. 2021 Jun 1;78(6):699-708.Full text  Abstract

328. Januel E, Hajage D, Labauge P, et al. Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open. 2023 Jun 1;6(6):e2319766.Full text  Abstract

329. Barzegar M, Mirmosayyeb O, Gajarzadeh M, et al. COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. 2021 Jul;8(4):e1001.Full text  Abstract

330. Aghajanian S, Shafiee A, Akhondi A, et al. The effect of COVID-19 on multiple sclerosis relapse: a systematic review and meta-analysis. Mult Scler Relat Disord. 2023 Nov 5;81:105128. Abstract

331. Giovanella L, Ruggeri RM, Ovčariček PP, et al. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021 Mar 11:1-8.Full text  Abstract

332. Malik J, Zaidi SMJ, Waqar AU, et al. Association of hypothyroidism with acute COVID-19: a systematic review. Expert Rev Endocrinol Metab. 2021 Sep;16(5):251-7. Abstract

333. Damara FA, Muchamad GR, Ikhsani R, et al. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021 Oct 22;15(6):102312.Full text  Abstract

334. Permana H, Soeriadi EA, Damara FA, et al. The prognostic values of thyroid disorders in predicting COVID-19 composite poor outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr. 2022 Mar 18;16(5):102464.Full text  Abstract

335. Putri C, Hariyanto TI, Hananto JE, et al. Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: a systematic review, meta-analysis, and meta-regression. Parkinsonism Relat Disord. 2021 Jun;87:155-61.Full text  Abstract

336. Chambergo-Michilot D, Barros-Sevillano S, Rivera-Torrejón O, et al. Factors associated with COVID-19 in people with Parkinson's disease: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3467-77.Full text  Abstract

337. Khoshnood RJ, Zali A, Tafreshinejad A, et al. Parkinson's disease and COVID-19: a systematic review and meta-analysis. Neurol Sci. 2022 Feb;43(2):775-83.Full text  Abstract

338. Jaiswal V, Alquraish D, Sarfraz Z, et al. The influence of coronavirus disease-2019 (COVID-19) on Parkinson's disease: an updated systematic review. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211039709.Full text  Abstract

339. Topless RK, Gaffo A, Stamp LK, et al. Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study. Lancet Rheumatol. 2022 Apr;4(4):e274-81.Full text  Abstract

340. Choi GJ, Kim HM, Kang H. The potential role of dyslipidemia in COVID-19 severity: an umbrella review of systematic reviews. J Lipid Atheroscler. 2020 Sep;9(3):435-48.Full text  Abstract

341. Zuin M, Rigatelli G, Bilato C, et al. Dyslipidaemia and mortality in COVID-19 patients: a meta-analysis. QJM. 2021 Oct 7;114(6):390-7.Full text  Abstract

342. Liu Y, Pan Y, Yin Y, et al. Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis. Virol J. 2021 Jul 27;18(1):157.Full text  Abstract

343. Atmosudigdo IS, Pranata R, Lim MA, et al. Dyslipidemia increases the risk of severe COVID-19: a systematic review, meta-analysis, and meta-regression. J Clin Exp Hepatol. 2021 Feb 8 [Epub ahead of print].Full text  Abstract

344. Kow CS, Hasan SS. The association between the use of statins and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2022 Mar;22(2):167-81.Full text  Abstract

345. Daniels LB, Ren J, Kumar K, et al. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One. 2021 Jul 15;16(7):e0254635.Full text  Abstract

346. Bergqvist R, Ahlqvist VH, Lundberg M, et al. HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: a registry-based cohort study. PLoS Med. 2021 Oct;18(10):e1003820.Full text  Abstract

347. Doglietto F, Vezzoli M, Gheza F, et al. Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID-19) in Italy. JAMA Surg. 2020 Jun 12;155(8):1-14.Full text  Abstract

348. Lei S, Jiang F, Su W, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 Apr 5:100331.Full text  Abstract

349. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet. 2020 Jul 4;396(10243):27-38.Full text  Abstract

350. Liu N, Zhang T, Ma L, et al. The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis. Blood Rev. 2020 Dec 8:100785.Full text  Abstract

351. Gutiérrez-Valencia M, Leache L, Librero J, et al. ABO blood group and risk of COVID-19 infection and complications: a systematic review and meta-analysis. Transfusion. 2022 Feb;62(2):493-505.Full text  Abstract

352. Soo KM, Chung KM, Mohd Azlan MAA, et al. The association of ABO and Rhesus blood type with the risks of developing SARS-CoV-2 infection: a meta-analysis. Trop Biomed. 2022 Mar 1;39(1):126-34.Full text  Abstract

353. Balaouras G, Eusebi P, Kostoulas P. Systematic review and meta-analysis of the effect of ABO blood group on the risk of SARS-CoV-2 infection. PLoS One. 2022 Jul 28;17(7):e0271451.Full text  Abstract

354. Franchini M, Cruciani M, Mengoli C, et al. ABO blood group and COVID-19: an updated systematic literature review and meta-analysis. Blood Transfus. 2021 May 12;19(4):317-26.Full text  Abstract

355. Butler EA, Parikh R, Grandi SM, et al. ABO and Rh blood groups and risk of infection: systematic review and meta-analysis. BMC Infect Dis. 2023 Nov 14;23(1):797.Full text  Abstract

356. Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide association study of severe Covid-19 with respiratory failure. N Engl J Med. 2020 Oct 15;383(16):1522-34.Full text  Abstract

357. Wu SC, Arthur CM, Wang J, et al. The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A. Blood Adv. 2021 Mar 9;5(5):1305-9.Full text  Abstract

358. Yamamoto S, Saito M, Tamura A, et al. The human microbiome and COVID-19: a systematic review. PLoS One. 2021 Jun 23;16(6):e0253293.Full text  Abstract

359. Cheng X, Zhang Y, Li Y, et al. Meta-analysis of 16S rRNA microbial data identified alterations of the gut microbiota in COVID-19 patients during the acute and recovery phases. BMC Microbiol. 2022 Nov 14;22(1):274.Full text  Abstract

360. Dhar D, Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 May 13;285:198018.Full text  Abstract

361. Zuo T, Zhang F, Lui GCY, et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology. 2020 Sep;159(3):944-55.Full text  Abstract

362. Gu S, Chen Y, Wu Z, et al. Alterations of the gut microbiota in patients with coronavirus disease 2019 or H1N1 influenza. Clin Infect Dis. 2020 Dec 17;71(10):2669-78.Full text  Abstract

363. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706.Full text  Abstract

364. Zheng HL, Guo ZL, Wang ML, et al. Effects of climate variables on the transmission of COVID-19: a systematic review of 62 ecological studies. Environ Sci Pollut Res Int. 2021 Oct;28(39):54299-316.Full text  Abstract

365. Centre for Evidence-Based Medicine; Hoang U, Jones NR. Is there an association between exposure to air pollution and severity of COVID-19 infection? 2020 [internet publication].Full text

366. Copat C, Cristaldi A, Fiore M, et al. The role of air pollution (PM and NO₂) in COVID-19 spread and lethality: a systematic review. Environ Res. 2020 Aug 24;191:110129.Full text  Abstract

367. Frontera A, Cianfanelli L, Vlachos K, et al. Severe air pollution links to higher mortality in COVID-19 patients: the “double-hit” hypothesis. J Infect. 2020 Aug;81(2):255-9.Full text  Abstract

368. Ogen Y. Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality. Sci Total Environ. 2020 Apr 11;726:138605.Full text  Abstract

369. Yu Z, Bellander T, Bergström A, et al. Association of short-term air pollution exposure with SARS-CoV-2 infection among young adults in Sweden. JAMA Netw Open. 2022 Apr 1;5(4):e228109.Full text  Abstract

370. Bowyer RCE, Varsavsky T, Thompson EJ, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2021 Jul;76(7):723-5.Full text  Abstract

371. World Health Organization. WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines. Nov 2023 [internet publication].Full text

372. Graña C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477.Full text  Abstract

373. Prasad S, Kalafat E, Blakeway H, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022 May 10;13(1):2414.Full text  Abstract

374. Carbone L, Trinchillo MG, Di Girolamo R, et al. COVID-19 vaccine and pregnancy outcomes: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2022 Dec;159(3):651-61.Full text  Abstract

375. Hagrass AI, Almadhoon HW, Al-Kafarna M, et al. Maternal and neonatal safety outcomes after SAR-CoV-2 vaccination during pregnancy: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2022 Jul 21;22(1):581.Full text  Abstract

376. Tormen M, Taliento C, Salvioli S, et al. Effectiveness and safety of COVID-19 vaccine in pregnant women: a systematic review with meta-analysis. BJOG. 2023 Mar;130(4):348-57.Full text  Abstract

377. Shafiee A, Kohandel Gargari O, Teymouri Athar MM, et al. COVID-19 vaccination during pregnancy: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023 Jan 20;23(1):45.Full text  Abstract

378. Badell ML, Dude CM, Rasmussen SA, et al. Covid-19 vaccination in pregnancy. BMJ. 2022 Aug 10;378:e069741.Full text  Abstract

379. Carlsen EØ, Magnus MC, Oakley L, et al. Association of COVID-19 vaccination during pregnancy with incidence of SARS-CoV-2 infection in infants. JAMA Intern Med. 2022 Aug 1;182(8):825-31.Full text  Abstract

380. Halasa NB, Olson SM, Staat MA, et al. Maternal vaccination and risk of hospitalization for Covid-19 among infants. N Engl J Med. 2022 Jul 14;387(2):109-19.Full text  Abstract

381. Hanna N, Heffes-Doon A, Lin X, et al. Detection of messenger RNA COVID-19 vaccines in human breast milk. JAMA Pediatr. 2022 Dec 1;176(12):1268-70.Full text  Abstract

382. Hamouda NI, Amin AM, Hasan MT, et al. Persistence of COVID-19 human milk antibodies after maternal COVID-19 vaccination: systematic review and meta-regression analysis. Cureus. 2024 May;16(5):e59500.Full text  Abstract

383. Du Y, Chen L, Shi Y. Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis. Front Public Health. 2022 Apr 14;10:829176.Full text  Abstract

384. Shafiq A, Salameh MA, Laswi I, et al. Neurological immune-related adverse events post-COVID-19 vaccination: a systematic review. J Clin Pharmacol. 2022 Mar;62(3):291-303.Full text  Abstract

385. Sessa F, Salerno M, Esposito M, et al. Autopsy findings and causality relationship between death and COVID-19 vaccination: a systematic review. J Clin Med. 2021 Dec 15;10(24):5876.Full text  Abstract

386. Bellinato F, Fratton Z, Girolomoni G, et al. Cutaneous adverse reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2022 Sep 6;10(9):1475.Full text  Abstract

387. Patrizio A, Ferrari SM, Elia G, et al. Graves' disease following SARS-CoV-2 vaccination: a systematic review. Vaccines (Basel). 2022 Sep 1;10(9):1445.Full text  Abstract

388. Baqi DH, Kakamad FH, Mahmood ZH, et al. Myocardial infarction following COVID-19 vaccine administration; a systematic review. Heliyon. 2022 Nov;8(11):e11385.Full text  Abstract

389. Abu Serhan H, Abdelaal A, Abuawwad MT, et al. Ocular vascular events following COVID-19 vaccines: a systematic review. Vaccines (Basel). 2022 Dec 14;10(12):2143.Full text  Abstract

390. Kwan AC, Ebinger JE, Wei J, et al. Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 infection. Nat Cardiovasc Res. 2022 Dec;1(12):1187-94.Full text  Abstract

391. Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: a multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024 Apr 2;42(9):2200-11.Full text  Abstract

392. Fraiman J, Erviti J, Jones M, et al. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Sep 22;40(40):5798-805.Full text  Abstract

393. Nafilyan V, Bermingham CR, Ward IL, et al. Risk of death following COVID-19 vaccination or positive SARS-CoV-2 test in young people in England. Nat Commun. 2023 Mar 27;14(1):1541.Full text  Abstract

394. Marchand G, Masoud AT, Medi S. Risk of all-cause and cardiac-related mortality after vaccination against COVID-19: a meta-analysis of self-controlled case series studies. Hum Vaccin Immunother. 2023 Aug 1;19(2):2230828.Full text  Abstract

395. Scholkmann F, May CA. ​COVID-19, post-acute COVID-19 syndrome (PACS, "long COVID") and post-COVID-19 vaccination syndrome (PCVS, "post-COVIDvac-syndrome"): similarities and differences. Pathol Res Pract. 2023 Jun;246:154497.Full text  Abstract

396. World Health Organization. Drugs to prevent COVID-19: living guideline. Mar 2023 [internet publication].Full text

397. National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. May 2024 [internet publication].Full text

398. World Health Organization. Therapeutics and COVID-19: living guideline. Nov 2023 [internet publication].Full text

399. National Institute for Health and Care Excellence. Tixagevimab plus cilgavimab for preventing COVID-19. Jun 2023 [internet publication.Full text

400. Alhumaid S, Al Mutair A, Alali J, et al. Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): a systematic review and meta-analysis. Diseases. 2022 Dec 1;10(4):118.Full text  Abstract

401. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Prophylaxis against covid-19: living systematic review and network meta-analysis. BMJ. 2021 Apr 26;373:n949.Full text  Abstract

402. Bartoszko JJ, Siemieniuk RAC, Kum E, et al. Update to living systematic review on prophylaxis against covid-19. BMJ. 2023 Mar 23;380:688.Full text  Abstract

403. World Health Organization. Infection prevention and control in the context of COVID-19: a guideline. Dec 2023 [internet publication].Full text

404. Schoberer D, Osmancevic S, Reiter L, et al. Rapid review and meta-analysis of the effectiveness of personal protective equipment for healthcare workers during the COVID-19 pandemic. Public Health Pract (Oxf). 2022 Dec;4:100280.Full text  Abstract

405. UK Health Security Agency. Face coverings and COVID-19: statement from an expert panel. Mar 2023 [internet publication].Full text

406. Wu G, Ji Q, Shi Y. A systematic review and meta-analysis of the efficacy of N95 respirators and surgical masks for protection against COVID-19. Prev Med Rep. 2023 Dec;36:102414.Full text  Abstract

407. Razai MS, Doerholt K, Ladhani S, et al. Coronavirus disease 2019 (covid-19): a guide for UK GPs. BMJ. 2020 Mar 5;368:m800.Full text  Abstract

408. World Health Organization. Advice for the public: coronavirus disease (COVID-19). Mar 2023 [internet publication].Full text

409. Jefferson T, Dooley L, Ferroni E, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207.Full text  Abstract

410. Chou R, Dana T, Jungbauer R, et al. Masks for prevention of respiratory virus infections, including SARS-CoV-2, in health care and community settings: a living rapid review. Ann Intern Med. 2020 Oct 6;173(7):542-55.Full text  Abstract

411. Chou R, Dana T. Major update: masks for prevention of SARS-CoV-2 in health care and community settings -final update of a living, rapid review. Ann Intern Med. 2023 Jun;176(6):827-35.Full text  Abstract

412. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, et al. Effectiveness of adding a mask recommendation to other public health measures to prevent SARS-CoV-2 infection in Danish mask wearers: a randomized controlled trial. Ann Intern Med. 2021 Mar;174(3):335-43.Full text  Abstract

413. Sandlund J, Duriseti R, Ladhani SN, et al. Child mask mandates for COVID-19: a systematic review. Arch Dis Child. 2024 Feb 19;109(3):e2.Full text  Abstract

414. Sharma SK, Mishra M, Mudgal SK. Efficacy of cloth face mask in prevention of novel coronavirus infection transmission: a systematic review and meta-analysis. J Educ Health Promot. 2020 Jul 28;9:192.Full text  Abstract

415. MacIntyre CR, Seale H, Dung TC, et al. A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ Open. 2015 Apr 22;5(4):e006577.Full text  Abstract

416. Lazzarino AI, Steptoe A, Hamer M, et al. Covid-19: important potential side effects of wearing face masks that we should bear in mind. BMJ. 2020 May 21;369:m2003.Full text  Abstract

417. Bakhit M, Krzyzaniak N, Scott AM, et al. Downsides of face masks and possible mitigation strategies: a systematic review and meta-analysis. BMJ Open. 2021 Feb 22;11(2):e044364.Full text  Abstract

418. Sezer H, Çınar D, Kılıç Akça N. The effect of prolonged use of surgical masks during face-to-face teaching on cognitive and physiological parameters of nursing students: a cross-sectional and descriptive study. Nurse Educ Pract. 2023 Sep 14;72:103779. Abstract

419. Bendavid E, Oh C, Bhattacharya J, et al. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. Eur J Clin Invest. 2021 Jan 5:e13484.Full text  Abstract

420. Burns J, Movsisyan A, Stratil JM, et al. International travel-related control measures to contain the COVID-19 pandemic: a rapid review. Cochrane Database Syst Rev. 2021 Mar 25;3(3):CD013717.Full text  Abstract

421. Viswanathan M, Kahwati L, Jahn B, et al. Universal screening for SARS-CoV-2 infection: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013718.Full text  Abstract

422. Nussbaumer-Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review. Cochrane Database Syst Rev. 2020 Sep 15;(9):CD013574.Full text  Abstract

423. Ho FK, Celis-Morales CA, Gray SR, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK Biobank prospective cohort study. BMJ Open. 2020 Nov 19;10(11):e040402.Full text  Abstract

424. Sharma S, Di Castelnuovo A, Cerletti C, et al. Diet quality and risk of SARS-CoV-2 infection or COVID-19: a systematic review of observational studies. Adv Nutr. 2023 Nov;14(6):1596-616.Full text  Abstract

425. NHS England. COVID-19 symptoms and what to do. Mar 2023 [internet publication].Full text

426. Luo X, Lv M, Zhang X, et al. Clinical manifestations of COVID-19: an overview of 102 systematic reviews with evidence mapping. J Evid Based Med. 2022 Sep;15(3):201-15.Full text  Abstract

427. Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440-8.Full text  Abstract

428. World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: scientific brief. May 2020 [internet publication].Full text

429. World Health Organization. Diagnostic testing for SARS-CoV-2: interim guidance. Sep 2020 [internet publication].Full text

430. World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection. Oct 2021 [internet publication].Full text

431. Government of the United Kingdom. Order COVID-19 rapid lateral flow tests [internet publication].Full text

432. Centers for Disease Control and Prevention. Considerations for SARS-CoV-2 antigen testing for healthcare providers testing individuals in the community. May 2023 [internet publication].Full text

433. British Society of Thoracic Imaging. Thoracic imaging in COVID-19 infection: guidance for the reporting radiologist - version 2. Mar 2020 [internet publication].Full text

434. Yu W, Guo Y, Zhang S, et al. Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: a systematic review and analysis. J Med Virol. 2022 Dec;94(12):5790-801.Full text  Abstract

435. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665.Full text  Abstract

436. Marquez C, Kerkhoff AD, Schrom J, et al. COVID-19 symptoms and duration of rapid antigen test positivity at a community testing and surveillance site during pre-Delta, Delta, and Omicron BA.1 periods. JAMA Netw Open. 2022 Oct 3;5(10):e2235844.Full text  Abstract

437. ZOE Health Study. What are the symptoms of Omicron? Oct 2022 [internet publication].Full text

438. Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet. 2022 Apr 23;399(10335):1618-24.Full text  Abstract

439. Chen KF, Feng TW, Wu CC, et al. Diagnostic accuracy of clinical signs and symptoms of COVID-19: a systematic review and meta-analysis to investigate the different estimates in a different stage of the pandemic outbreak. J Glob Health. 2023 Jul 14;13:06026.Full text  Abstract

440. Matar R, Alrahmani L, Monzer N, et al. Clinical presentation and outcomes of pregnant women with coronavirus disease 2019: a systematic review and meta-analysis. Clin Infect Dis. 2021 Feb 1;72(3):521-33.Full text  Abstract

441. Lechien JR, Chetrit A, Chekkoury-Idrissi Y, et al. Parotitis-like symptoms associated with COVID-19, France, March-April 2020. Emerg Infect Dis. 2020 Jun 3;26(9).Full text  Abstract

442. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, et al. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021 Apr;27 Suppl 3:710-2.Full text  Abstract

443. Wambier CG, Vaño-Galván S, McCoy J, et al. Androgenetic alopecia present in the majority of hospitalized COVID-19 patients: the "Gabrin sign". J Am Acad Dermatol. 2020 May 21;83(2):680-2.Full text  Abstract

444. Giannos P, Katsikas Triantafyllidis K, Geropoulos G, et al. Persistent hiccups as an atypical presentation of SARS-CoV-2 infection: a systematic review of case reports. Front Neurol. 2022 Apr 4;13:819624.Full text  Abstract

445. Musuuza JS, Watson L, Parmasad V, et al. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS One. 2021 May 6;16(5):e0251170.Full text  Abstract

446. Cong B, Deng S, Wang X, et al. The role of respiratory co-infection with influenza or respiratory syncytial virus in the clinical severity of COVID-19 patients: a systematic review and meta-analysis. J Glob Health. 2022 Sep 17;12:05040.Full text  Abstract

447. Wang Y, Xu J, Wang Y, et al. Prevalence of comorbid tuberculosis amongst COVID-19 patients: a rapid review and meta-analysis. Int J Clin Pract. 2021 Nov;75(11):e14867.Full text  Abstract

448. Dadashi M, Dadashi A, Sameni F, et al. SARS-CoV-2 and HIV co-infection; clinical features, diagnosis, and treatment strategies: a systematic review and meta-analysis. Gene Rep. 2022 Jun;27:101624.Full text  Abstract

449. Mohamed AH, Eltyeb E, Said B, et al. COVID-19 and malaria co-infection: a systematic review of clinical outcomes in endemic areas. PeerJ. 2024;12:e17160.Full text  Abstract

450. Schultz CM, Burke LA, Kent DA. A systematic review and meta-analysis of the initial literature regarding COVID-19 symptoms in children in the United States. J Pediatr Health Care. 2023 Jul-Aug;37(4):425-37.Full text  Abstract

451. Mahase E. Covid-19: Children less likely to report fever, persistent cough, or appetite loss, large UK study finds. BMJ. 2021 Feb 10;372:n408.Full text  Abstract

452. Karron RA, Hetrich MK, Na YB, et al. Assessment of clinical and virological characteristics of SARS-CoV-2 infection among children aged 0 to 4 years and their household members. JAMA Netw Open. 2022 Aug 1;5(8):e2227348.Full text  Abstract

453. Seery V, Raiden S, Russo C, et al. Antibody response against SARS-CoV-2 variants of concern in children infected with pre-Omicron variants: an observational cohort study. EBioMedicine. 2022 Sep;83:104230.Full text  Abstract

454. Bahl A, Mielke N, Johnson S, et al. Severe COVID-19 outcomes in pediatrics: an observational cohort analysis comparing Alpha, Delta, and Omicron variants. Lancet Reg Health Am. 2023 Feb;18:100405.Full text  Abstract

455. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. Pediatr Infect Dis J. 2020 Aug;39(8):e212. Abstract

456. Chacón-Aguilar R, Osorio-Cámara JM, Sanjurjo-Jimenez I, et al. COVID-19: fever syndrome and neurological symptoms in a neonate. An Pediatr (Engl Ed). 2020 Apr 27;92(6):373-4.Full text  Abstract

457. Sinelli MT, Paterlini G, Citterio M, et al. Early neonatal SARS-CoV-2 infection manifesting with hypoxemia requiring respiratory support. Pediatrics. 2020 Jul;146(1):e20201121.Full text  Abstract

458. Rubens JH, Akindele NP, Tschudy MM, et al. Acute covid-19 and multisystem inflammatory syndrome in children. BMJ. 2021 Mar 1;372:n385.Full text  Abstract

459. Alhumaid S, Alabdulqader M, Al Dossary N, et al. Global coinfections with bacteria, fungi, and respiratory viruses in children with SARS-CoV-2: a systematic review and meta-analysis. Trop Med Infect Dis. 2022 Nov 15;7(11):380.Full text  Abstract

460. Adams K, Tastad KJ, Huang S, et al. Prevalence of SARS-CoV-2 and influenza coinfection and clinical characteristics among children and adolescents aged <18 years who were hospitalized or died with influenza: United States, 2021-22 influenza season. MMWR Morb Mortal Wkly Rep. 2022 Dec 16;71(50):1589-96.Full text  Abstract

461. Vasudevan RS, Bin Thani K, Aljawder D, et al. The stethoscope: a potential vector for COVID-19? Eur Heart J. 2020 Sep 21;41(36):3393-5.Full text  Abstract

462. Ikeuchi K, Saito M, Yamamoto S, et al. Relative bradycardia in patients with mild-to-moderate coronavirus disease, Japan. Emerg Infect Dis. 2020 Jul 1;26(10).Full text  Abstract

463. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90.Full text  Abstract

464. NHS England. Pulse oximetry to detect early deterioration of patients with COVID-19 in primary and community care settings. Oct 2022 [internet publication].Full text

465. Bhimraj A, Morgan RL, Hirsch Shumaker A, et al. Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19. Jun 2023 [internet publication].Full text

466. Xie J, Tong Z, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020 May;46(5):837-40.Full text  Abstract

467. Shi C, Goodall M, Dumville J, et al. The accuracy of pulse oximetry in measuring oxygen saturation by levels of skin pigmentation: a systematic review and meta-analysis. BMC Med. 2022 Aug 16;20(1):267.Full text  Abstract

468. US Food and Drug Administration. Pulse oximeters. Nov 2023 [internet publication].Full text

469. Royal College of Physicians. NEWS2 and deterioration in COVID-19. Jul 2020 [internet publication].Full text

470. Zhang K, Zhang X, Ding W, et al. The prognostic accuracy of national early warning score 2 on predicting clinical deterioration for patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 9;8:699880.Full text  Abstract

471. Lalueza A, Lora-Tamayo J, de la Calle C, et al. The early use of sepsis scores to predict respiratory failure and mortality in non-ICU patients with COVID-19. Rev Clin Esp (Barc). 2022 May;222(5):293-8.Full text  Abstract

472. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020 Jun;92(6):577-83.Full text  Abstract

473. Zhu J, Zhong Z, Ji P, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020 Apr;8(2).Full text  Abstract

474. Zhang ZL, Hou YL, Li DT, et al. Laboratory findings of COVID-19: a systematic review and meta-analysis. Scand J Clin Lab Invest. 2020 May 23:1-7.Full text  Abstract

475. Wu H, Zhu H, Yuan C, et al. Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China. JAMA Netw Open. 2020 Jun 1;3(6):e2010895.Full text  Abstract

476. Henry BM, Benoit SW, de Oliveira MHS, et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem. 2020 Jul;81:1-8.Full text  Abstract

477. Kronbichler A, Kresse D, Yoon S, et al. Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis. Int J Infect Dis. 2020 Sep;98:180-6.Full text  Abstract

478. Peeling RW, Heymann DL, Teo YY, et al. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2021 Dec 20;399(10326):757-68.Full text  Abstract

479. World Health Organization. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states. Jan 2022 [internet publication].Full text

480. Soni A, Herbert C, Filippaios A, et al. Comparison of rapid antigen tests' performance between Delta and Omicron variants of SARS-CoV-2: a secondary analysis from a serial home self-testing study. Ann Intern Med. 2022 Dec;175(12):1685-92.Full text  Abstract

481. World Health Organization. WHO policy brief: COVID-19 testing, 14 September 2022. Sep 2022 [internet publication].Full text

482. World Health Organization. Recommendations for national SARS-CoV-2 testing strategies and diagnostic capacities: interim guidance. Jun 2021 [internet publication].Full text

483. UK Health Security Agency. COVID-19: testing from 1 April 2024. Mar 2024 [internet publication].Full text

484. Centers for Disease Control and Prevention. Overview of testing for SARS-CoV-2, the virus that causes COVID-19. Mar 2024 [internet publication].Full text

485. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. Sep 2023 [internet publication].Full text

486. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. Jul 2022 [internet publication].Full text

487. Gupta K, Bellino PM, Charness ME. Adverse effects of nasopharyngeal swabs: three-dimensional printed versus commercial swabs. Infect Control Hosp Epidemiol. 2021 May;42(5):641-2.Full text  Abstract

488. Koskinen A, Tolvi M, Jauhiainen M, et al. Complications of COVID-19 nasopharyngeal swab test. JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):672-4.Full text  Abstract

489. Sullivan CB, Schwalje AT, Jensen M, et al. Cerebrospinal fluid leak after nasal swab testing for coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1179-81.Full text  Abstract

490. Knížek Z, Michálek R, Vodicka J, et al. Cribriform plate injury after nasal swab testing for COVID-19. JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):915-7.Full text  Abstract

491. Jarrom D, Elston L, Washington J, et al. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evid Based Med. 2022 Feb;27(1):33-45.Full text  Abstract

492. World Health Organization. Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing. Mar 2022 [internet publication].Full text

493. Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020 Sep 8;370:m3325.Full text  Abstract

494. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020 Jun;26(6):845-8.Full text  Abstract

495. Qu J, Wu C, Li X, et al. Profile of immunoglobulin G and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Nov 19;71(16):2255-8.Full text  Abstract

496. Centers for Disease Control and Prevention. Interim guidelines for COVID-19 antibody testing. Dec 2022 [internet publication].Full text

497. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing. Feb 2024 [internet publication].Full text

498. World Health Organization. Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief. Apr 2020 [internet publication].Full text

499. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020 Jul 1;370:m2516.Full text  Abstract

500. World Health Organization. WHO information notice for IVD users 2020/05. Jan 2021 [internet publication].Full text

501. Centre for Evidence-Based Medicine; Jefferson T, Heneghan C, Spencer EA, et al. Are you infectious if you have a positive PCR test result for COVID-19? Aug 2020 [internet publication].Full text

502. Jefferson T, Spencer EA, Brassey J, et al. Viral cultures for coronavirus disease 2019 infectivity assessment: a systematic review. Clin Infect Dis. 2021 Dec 6;73(11):e3884-99.Full text  Abstract

503. Watson J, Whiting PF, Brush JE. Interpreting a covid-19 test result. BMJ. 2020 May 12;369:m1808.Full text  Abstract

504. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 Dec 17;71(10):2663-6.Full text  Abstract

505. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-61.Full text  Abstract

506. Tassetto M, Garcia-Knight M, Anglin K, et al. Detection of higher cycle threshold values in culturable SARS-CoV-2 Omicron BA.1 sublineage compared with pre-Omicron variant specimens: San Francisco Bay Area, California, July 2021 - March 2022. MMWR Morb Mortal Wkly Rep. 2022 Sep 9;71(36):1151-4.Full text  Abstract

507. Surkova E, Nikolayevskyy V, Drobniewski F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir Med. 2020 Dec;8(12):1167-8.Full text  Abstract

508. Floriano I, Silvinato A, Bernardo WM, et al. Accuracy of the polymerase chain reaction (PCR) test in the diagnosis of acute respiratory syndrome due to coronavirus: a systematic review and meta-analysis. Rev Assoc Med Bras (1992). 2020 Jul;66(7):880-8.Full text  Abstract

509. Public Health Laboratory Network. PHLN guidance on nucleic acid test result interpretation for SARS-CoV-2. Jul 2022 [internet publication].Full text

510. Australian Government Department of Health. COVID-19 testing in Australia: information for health professionals. May 2024 [internet publication].Full text

511. US Food and Drug Administration. CDC 2019-novel coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel. Mar 2023 [internet publication].Full text

512. Government Office for Science; Scientific Advisory Group for Emergencies. Impact of false-positives and false-negatives in the UK’s COVID-19 RT-PCR testing programme. May 2022 [internet publication].Full text

513. US Food and Drug Administration. Genetic variants of SARS-CoV-2 may lead to false negative results with molecular tests for detection of SARS-CoV-2: letter to clinical laboratory staff and health care providers. Dec 2021 [internet publication].Full text

514. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, et al. False-negative results of initial RT-PCR assays for COVID-19: a systematic review. PLoS One. 2020 Dec 10;15(12):e0242958.Full text  Abstract

515. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 Aug 18;173(4):262-7.Full text  Abstract

516. Tsang NNY, So HC, Ng KY, et al. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis. 2021 Apr 12;21(9):1233-45.Full text  Abstract

517. Zhou Y, O'Leary TJ. Relative sensitivity of anterior nares and nasopharyngeal swabs for initial detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis. PLoS One. 2021 Jul 20;16(7):e0254559.Full text  Abstract

518. Fowler T, Chapman D, Futschik ME, et al. Self-swabbing versus assisted swabbing for viral detection by qRT-PCR: the experience from SARS-CoV-2 based on a meta-analysis of six prospectively designed evaluations conducted in a UK setting. Eur J Clin Microbiol Infect Dis. 2024 Jun 10 [Epub ahead of print].Full text  Abstract

519. Bastos ML, Perlman-Arrow S, Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021 Apr;174(4):501-10.Full text  Abstract

520. Butler-Laporte G, Lawandi A, Schiller I, et al. Comparison of saliva and nasopharyngeal swab nucleic acid amplification testing for detection of SARS-CoV-2: a systematic review and meta-analysis. JAMA Intern Med. 2021 Mar 1;181(3):353-60.Full text  Abstract

521. Cañete MG, Valenzuela IM, Garcés PC, et al. Saliva sample for the massive screening of SARS-CoV-2 infection: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2021 May;131(5):540-8.Full text  Abstract

522. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. Diagnostics (Basel). 2021 Feb 21;11(2):363.Full text  Abstract

523. Atieh MA, Guirguis M, Alsabeeha NHM, et al. The diagnostic accuracy of saliva testing for SARS-CoV-2: a systematic review and meta-analysis. Oral Dis. 2022 Nov;28 (Suppl 2):2347-61.Full text  Abstract

524. Ibrahimi N, Delaunay-Moisan A, Hill C, et al. Screening for SARS-CoV-2 by RT-PCR: saliva or nasopharyngeal swab? Rapid review and meta-analysis. PLoS One. 2021 Jun 10;16(6):e0253007.Full text  Abstract

525. Wagenhäuser I, Knies K, Rauschenberger V, et al. Clinical performance evaluation of SARS-CoV-2 rapid antigen testing in point of care usage in comparison to RT-qPCR. EBioMedicine. 2021 Jun 26;69:103455.Full text  Abstract

526. Brümmer LE, Katzenschlager S, Gaeddert M, et al. Accuracy of novel antigen rapid diagnostics for SARS-CoV-2: a living systematic review and meta-analysis. PLoS Med. 2021 Aug;18(8):e1003735.Full text  Abstract

527. Dinnes J, Sharma P, Berhane S, et al. Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection. Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705.Full text  Abstract

528. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ. 2021 Jul 6;374:n1637.Full text  Abstract

529. US Food and Drug Administration. Lab alert: FDA issues safety letter about potential for false positive results with antigen tests for rapid detection of SARS-CoV-2. Jan 2023 [internet publication].Full text

530. US Food and Drug Administration. At-home COVID-19 antigen tests - take steps to reduce your risk of false negative: FDA safety communication. Nov 2022 [internet publication].Full text

531. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652.Full text  Abstract

532. World Health Organization. Use of chest imaging in COVID-19: a rapid advice guide. Jun 2020 [internet publication].Full text

533. Poon LC, Yang H, Kapur A, et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: information for healthcare professionals. Int J Gynaecol Obstet. 2020 Jun;149(3):273-86.Full text  Abstract

534. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Jul 27;80:229-38.Full text  Abstract

535. Ebrahimzadeh S, Islam N, Dawit H, et al. Thoracic imaging tests for the diagnosis of COVID-19. Cochrane Database Syst Rev. 2022 May 16;5(5):CD013639.Full text  Abstract

536. Centre for Evidence-Based Medicine; Park JY, Freer R, Stevens R, et al. The accuracy of chest CT in the diagnosis of COVID-19: an umbrella review. Mar 2021 [internet publication].Full text

537. Tavare AN, Braddy A, Brill S, et al. Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT. Thorax. 2020 Jul;75(7):537-8.Full text  Abstract

538. American College of Radiology. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. Mar 2020 [internet publication].Full text

539. Nam BD, Hong H, Yoon SH. Diagnostic performance of standardized typical CT findings for COVID-19: a systematic review and meta-analysis. Insights Imaging. 2023 May 24;14(1):96.Full text  Abstract

540. Kim H, Hong H, Yoon SH. Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis. Radiology. 2020 Apr 17:201343.Full text  Abstract

541. Lv M, Wang M, Yang N, et al. Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis. Ann Transl Med. 2020 May;8(10):622.Full text  Abstract

542. Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020 Sep;92(9):1518-24.Full text  Abstract

543. Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-93.Full text  Abstract

544. Long C, Xu H, Shen Q, et al. Diagnosis of the coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol. 2020 Mar 25;126:108961.Full text  Abstract

545. Chen C, Zhu C, Yan D, et al. The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): a systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-64.Full text  Abstract

546. Sun P, Qie S, Liu Z, et al. Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: a single arm meta-analysis. J Med Virol. 2020 Jun;92(6):612-7.Full text  Abstract

547. Ojha V, Mani A, Pandey NN, et al. CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients. Eur Radiol. 2020 Nov;30(11):6129-38.Full text  Abstract

548. Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020 Nov 11;72:75-82.Full text  Abstract

549. Hossein H, Ali KM, Hosseini M, et al. Value of chest computed tomography scan in diagnosis of COVID-19: a systematic review and meta-analysis. Clin Transl Imaging. 2020 Oct 12:1-13.Full text  Abstract

550. Zhao D, Yao F, Wang L, et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis. 2020 Jul 28;71(15):756-61.Full text  Abstract

551. Oshay RR, Chen MYC, Fields BKK, et al. COVID-19 in pregnancy: a systematic review of chest CT findings and associated clinical features in 427 patients. Clin Imaging. 2021 Jan 13;75:75-82.Full text  Abstract

552. Wang JG, Mo YF, Su YH, et al. Computed tomography features of COVID-19 in children: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Sep 24;100(38):e22571.Full text  Abstract

553. Ghodsi A, Bijari M, Alamdaran SA, et al. Chest computed tomography findings of COVID-19 in children younger than 1 year: a systematic review. World J Pediatr. 2021 Jun;17(3):234-41.Full text  Abstract

554. Gil-Rodríguez J, Martos-Ruiz M, Benavente-Fernández A, et al. Lung ultrasound score severity cut-off points in COVID-19 pneumonia: a systematic review and validating cohort. Med Clin (Engl Ed). 2023 Jun 23;160(12):531-9.Full text  Abstract

555. Gil-Rodríguez J, Pérez de Rojas J, Aranda-Laserna P, et al. Ultrasound findings of lung ultrasonography in COVID-19: a systematic review. Eur J Radiol. 2022 Jan 20;148:110156.Full text  Abstract

556. Moro F, Buonsenso D, Moruzzi MC, et al. How to perform lung ultrasound in pregnant women with suspected COVID-19 infection. Ultrasound Obstet Gynecol. 2020 May;55(5):593-8.Full text  Abstract

557. Denina M, Scolfaro C, Silvestro E, et al. Lung ultrasound in children with COVID-19. Pediatrics. 2020 Jul;146(1):e20201157.Full text  Abstract

558. Caroselli C, Blaivas M, Falzetti S. Diagnostic imaging in newborns, children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): is there a realistic alternative to lung high-resolution computed tomography (HRCT) and chest x-rays? A systematic review of the literature. Ultrasound Med Biol. 2021 Nov;47(11):3034-40.Full text  Abstract

559. Pillai K, Hewage S, Harky A. The role of the lung ultrasound in coronavirus disease 2019: a systematic review. J Med Ultrasound. 2020 Oct-Dec;28(4):207-12.Full text  Abstract

560. Song G, Qiao W, Wang X, et al. Association of lung ultrasound score with mortality and severity of COVID-19: a meta-analysis and trial sequential analysis. Int J Infect Dis. 2021 Jul;108:603-9.Full text  Abstract

561. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis of 17515 patients. PLoS One. 2021;16(4):e0249788.Full text  Abstract

562. Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020 Apr 23;382(17):1663-5.Full text  Abstract

563. ZOE COVID Symptom Study. What are the most common COVID symptoms? Dec 2022 [internet publication].Full text

564. Song WJ, Hui CKM, Hull JH, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med. 2021 May;9(5):533-44.Full text  Abstract

565. Talukder A, Razu SR, Alif SM, et al. Association between symptoms and severity of disease in hospitalised novel coronavirus (COVID-19) patients: a systematic review and meta-analysis. J Multidiscip Healthc. 2022 May 12;15:1101-10.Full text  Abstract

566. Cardoso CC, Rossi ÁD, Galliez RM, et al. Olfactory dysfunction in patients with mild COVID-19 during Gamma, Delta, and Omicron waves in Rio de Janeiro, Brazil. JAMA. 2022 Aug 9;328(6):582-3.Full text  Abstract

567. Esmaeili M, Abdi F, Shafiee G, et al. Olfactory and gustatory dysfunction in 2019 novel coronavirus: an updated systematic review and meta-analysis. Int J Prev Med. 2021 Dec 14;12:170.Full text  Abstract

568. Eliezer M, Hautefort C, Hamel AL, et al. Sudden and complete olfactory loss function as a possible symptom of COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-5.Full text  Abstract

569. Jafar A, Lasso A, Shorr R, et al. Olfactory recovery following infection with COVID-19: a systematic review. PLoS One. 2021 Nov 9;16(11):e0259321.Full text  Abstract

570. Tan BKJ, Han R, Zhao JJ, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. BMJ. 2022 Jul 27;378:e069503.Full text  Abstract

571. Renaud M, Thibault C, Le Normand F, et al. Clinical outcomes for patients with anosmia 1 year after COVID-19 diagnosis. JAMA Netw Open. 2021 Jun 1;4(6):e2115352.Full text  Abstract

572. Boscolo-Rizzo P, Fabbris C, Polesel J, et al. Two-year prevalence and recovery rate of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2022 Sep 1;148(9):889-91.Full text  Abstract

573. Walker A, Kelly C, Pottinger G, et al. Parosmia: a common consequence of covid-19. BMJ. 2022 Apr 27;377:e069860.Full text  Abstract

574. Ferraro S, Tuccori M, Convertino I, et al. Olfactory and gustatory impairments in COVID-19 patients: role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 May;87(5):2186-8.Full text  Abstract

575. Chaudhry ZS, Nellessen N, Reis C, et al. The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 2022 Nov 22;39(6):1116-34. Abstract

576. Korres G, Kitsos DK, Kaski D, et al. The prevalence of dizziness and vertigo in COVID-19 patients: a systematic review. Brain Sci. 2022 Jul 20;12(7):948.Full text  Abstract

577. Shao SC, Lai CC, Chen YH, et al. Prevalence, incidence and mortality of delirium in patients with COVID-19: A systematic review and meta-analysis. Age Ageing. 2021 Sep 11;50(5):1445-53.Full text  Abstract

578. Pun BT, Badenes R, Heras La Calle G, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. 2021 Mar;9(3):239-50.Full text  Abstract

579. Bolia R, Dhanesh Goel A, Badkur M, et al. Gastrointestinal manifestations of pediatric coronavirus disease and their relationship with a severe clinical course: a systematic review and meta-analysis. J Trop Pediatr. 2021 May 17;67(2):fmab051.Full text  Abstract

580. Aziz M, Haghbin H, Lee-Smith W, et al. Gastrointestinal predictors of severe COVID-19: systematic review and meta-analysis. Ann Gastroenterol. 2020 Nov-Dec;33(6):615-30.Full text  Abstract

581. Zeng W, Qi K, Ye M, et al. Gastrointestinal symptoms are associated with severity of coronavirus disease 2019: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):168-76.Full text  Abstract

582. Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y). 2022 Jun 10;3(6):371-87.Full text  Abstract

583. Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021 May;184(5):880-7.Full text

584. Schwartzberg LN, Advani S, Clancy DC, et al. A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis. Skin Health Dis. 2021 Jun;1(2):e20.Full text  Abstract

585. Dondi A, Sperti G, Gori D, et al. Epidemiology and clinical evolution of non-multisystem inflammatory syndrome (MIS-C) dermatological lesions in pediatric patients affected by SARS-CoV-2 infection: a systematic review of the literature. Eur J Pediatr. 2022 Oct;181(10):3577-93.Full text  Abstract

586. Mashayekhi F, Seirafianpour F, Pour Mohammad A, et al. Severe and life-threatening COVID-19-related mucocutaneous eruptions: a systematic review. Int J Clin Pract. 2021 Aug 19:e14720.Full text  Abstract

587. Discepolo V, Catzola A, Pierri L, et al. Bilateral chilblain-like lesions of the toes characterized by microvascular remodeling in adolescents during the COVID-19 pandemic. JAMA Netw Open. 2021 Jun 1;4(6):e2111369.Full text  Abstract

588. Gehlhausen JR, Little AJ, Ko CJ, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2122090119.Full text  Abstract

589. Christie B. Sixty seconds on . . . covid toe. BMJ. 2022 Mar 21;376:o742.Full text  Abstract

590. Inomata T, Kitazawa K, Kuno T, et al. Clinical and prodromal ocular symptoms in coronavirus disease: a systematic review and meta-analysis. Invest Ophthalmol Vis Sci. 2020 Aug 3;61(10):29.Full text  Abstract

591. Sen S, Kannan NB, Kumar J, et al. Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. Int Ophthalmol. 2022 Jan;42(1):323-36.Full text  Abstract

592. Ullah I, Sohail A, Shah MUFA, et al. Central retinal vein occlusion in patients with COVID-19 infection: a systematic review. Ann Med Surg (Lond). 2021 Oct 8:102898.Full text  Abstract

593. Modjtahedi BS, Do D, Luong TQ, et al. Changes in the incidence of retinal vascular occlusions after COVID-19 diagnosis. JAMA Ophthalmol. 2022 May 1;140(5):523-7.Full text  Abstract

594. Zhong Y, Wang K, Zhu Y, et al. Ocular manifestations in COVID-19 patients: a systematic review and meta-analysis. Travel Med Infect Dis. 2021 Nov-Dec;44:102191.Full text  Abstract

595. Casey K, Iteen A, Nicolini R, et al. COVID-19 pneumonia with hemoptysis: acute segmental pulmonary emboli associated with novel coronavirus infection. Am J Emerg Med. 2020 Jul;38(7):1544.Full text  Abstract

596. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11.Full text  Abstract

597. Meng X, Wang J, Sun J, et al. COVID-19 and sudden sensorineural hearing loss: a systematic review. Front Neurol. 2022 Apr 28;13:883749.Full text  Abstract

598. Erbaş GS, Botsali A, Erden N, et al. COVID-19-related oral mucosa lesions among confirmed SARS-CoV-2 patients: a systematic review. Int J Dermatol. 2022 Jan;61(1):20-32.Full text  Abstract

599. Holcomb ZE, Hussain S, Huang JT, et al. Reactive infectious mucocutaneous eruption associated with SARS-CoV-2 infection. JAMA Dermatol. 2021 May 1;157(5):603-5.Full text  Abstract

600. Bhujel N, Zaheer K, Singh RP. Oral mucosal lesions in patients with COVID-19: a systematic review. Br J Oral Maxillofac Surg. 2021 Nov;59(9):1024-30.Full text  Abstract

601. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: molecular diagnostic testing. Sep 2023 [internet publication].Full text

602. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing. Dec 2022 [internet publication].Full text

603. Danwang C, Endomba FT, Nkeck JR, et al. A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19). Biomark Res. 2020 Aug 31;8:37.Full text  Abstract

604. Zuin M, Rigatelli G, Quadretti L, et al. Prognostic role of anemia in COVID-19 patients: a meta-analysis. Infect Dis Rep. 2021 Oct 31;13(4):930-7.Full text  Abstract

605. Foy BH, Carlson JCT, Reinertsen E, et al. Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection. JAMA Netw Open. 2020 Sep 1;3(9):e2022058.Full text  Abstract

606. Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis. Cytometry A. 2020 Aug;97(8):772-6.Full text  Abstract

607. Chen W, Li Z, Yang B, et al. Delayed-phase thrombocytopenia in patients of coronavirus disease 2019 (COVID-19). Br J Haematol. 2020 Jul;190(2):179-84.Full text  Abstract

608. Chen D, Li X, Song Q, et al. Assessment of hypokalemia and clinical characteristics in patients with coronavirus disease 2019 in Wenzhou, China. JAMA Netw Open. 2020 Jun 1;3(6):e2011122.Full text  Abstract

609. Alemzadeh E, Alemzadeh E, Ziaee M, et al. The effect of low serum calcium level on the severity and mortality of Covid patients: a systematic review and meta-analysis. Immun Inflamm Dis. 2021 Dec;9(4):1219-28.Full text  Abstract

610. Akbar MR, Pranata R, Wibowo A, et al. The prognostic value of hyponatremia for predicting poor outcome in patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jun 14;8:666949.Full text  Abstract

611. Lazarus G, Audrey J, Kharisma Wangsaputra V, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: a systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2020 Dec 9:108561.Full text  Abstract

612. Handayani DR, Juliastuti H, Nawangsih EN, et al. Prognostic value of fasting hyperglycemia in patients with COVID-19: diagnostic test accuracy meta-analysis. Obes Med. 2021 Apr 4:100333.Full text  Abstract

613. Klonoff DC, Messler JC, Umpierrez GE, et al. Association between achieving inpatient glycemic control and clinical outcomes in hospitalized patients with COVID-19: a multicenter, retrospective hospital-based analysis. Diabetes Care. 2021 Feb;44(2):578-85.Full text  Abstract

614. Nugroho J, Wardhana A, Mulia EP, et al. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: a meta-analysis. Clin Hemorheol Microcirc. 2021;77(2):221-31.Full text  Abstract

615. Shah S, Shah K, Patel SB, et al. Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis. Cardiol Rev. 2020 Nov/Dec;28(6):295-302. Abstract

616. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiology. 2020 Apr 23:201561.Full text  Abstract

617. Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020 Jul 31;87(8):461-8.Full text  Abstract

618. Zinellu A, Paliogiannis P, Carru C, et al. INR and COVID-19 severity and mortality: a systematic review with meta-analysis and meta-regression. Adv Med Sci. 2021 Jul 21;66(2):372-80.Full text  Abstract

619. Rostami M, Mansouritorghabeh H, Parsa-Kondelaji M. High levels of Von Willebrand factor markers in COVID-19: a systematic review and meta-analysis. Clin Exp Med. 2021 Nov 6;1-11.Full text  Abstract

620. Wungu CDK, Khaerunnisa S, Putri EAC, et al. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis. 2021 Mar 9;105:551-9.Full text  Abstract

621. Yitbarek GY, Walle Ayehu G, Asnakew S, et al. The role of C-reactive protein in predicting the severity of COVID-19 disease: a systematic review. SAGE Open Med. 2021 Oct 11;9:20503121211050755.Full text  Abstract

622. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 Jun 14;42(23):2270-9.Full text  Abstract

623. Kumar A, Karn E, Trivedi K, et al. Procalcitonin as a predictive marker in COVID-19: a systematic review and meta-analysis. PLoS One. 2022 Sep 9;17(9):e0272840.Full text  Abstract

624. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 May;55(5):1169-74.Full text  Abstract

625. Cheng L, Li H, Li L, et al. Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Lab Anal. 2020 Oct 19:e23618.Full text  Abstract

626. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 28;395(10229):1033-4.Full text  Abstract

627. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: a systematic review and meta-analysis. J Trop Pediatr. 2021 Jul 2;67(3):fmaa045.Full text  Abstract

628. Jari R, Alfuraih AM, McLaughlan JR. The diagnostic performance of lung ultrasound for detecting COVID-19 in emergency departments: a systematic review and meta-analysis. J Clin Ultrasound. 2022 Jun;50(5):618-27.Full text  Abstract

629. Centre for Evidence-Based Medicine; Heneghan C, Pluddemann A, Mahtani KR. Differentiating viral from bacterial pneumonia. Apr 2020 [internet publication].Full text

630. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging. 2020 May;101(5):263-8.Full text  Abstract

631. Pormohammad A, Ghorbani S, Khatami A, et al. Comparison of influenza type A and B with COVID-19: a global systematic review and meta-analysis on clinical, laboratory and radiographic findings. Rev Med Virol. 2020 Oct 9:e2179.Full text  Abstract

632. Czubak J, Stolarczyk K, Orzeł A, et al. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: a systematic literature review. Adv Clin Exp Med. 2021 Jan;30(1):109-14.Full text  Abstract

633. Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles J, et al. Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicenter PCR-based case-control study. Eur J Neurol. 2020 Sep;27(9):1738-41.Full text  Abstract

634. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 era. JAMA. 2020 Oct 6;324(13):1342-3.Full text  Abstract

635. Song X, Delaney M, Shah RK, et al. Comparison of clinical features of COVID-19 vs seasonal influenza A and B in US children. JAMA Netw Open. 2020 Sep 1;3(9):e2020495.Full text  Abstract

636. Guan Z, Chen C, Li Y, et al. Impact of coinfection with SARS-CoV-2 and influenza on disease severity: a systematic review and meta-analysis. Front Public Health. 2021 Dec 10;9:773130.Full text  Abstract

637. Dao TL, Hoang VT, Colson P, et al. Co-infection of SARS-CoV-2 and influenza viruses: a systematic review and meta-analysis. J Clin Virol Plus. 2021 Sep;1(3):100036.Full text  Abstract

638. Liu M, Zeng W, Wen Y, et al. COVID-19 pneumonia: CT findings of 122 patients and differentiation from influenza pneumonia. Eur Radiol. 2020 Oct;30(10):5463-9.Full text  Abstract

639. Yin Z, Kang Z, Yang D, et al. A comparison of clinical and chest CT findings in patients with influenza A (H1N1) virus infection and coronavirus disease (COVID-19). AJR Am J Roentgenol. 2020 May 26:1-7.Full text  Abstract

640. Luo Y, Yuan X, Xue Y, et al. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus. Int J Infect Dis. 2020 May 1;95:436-40.Full text  Abstract

641. Zarei F, Reza J, Sefidbakht S, et al. Aspiration pneumonia or COVID-19 infection: a diagnostic challenge. Acad Radiol. 2020 Jul;27(7):1046.Full text  Abstract

642. Kaya T, Dilek A, Ozaras R, et al. COVID 19 and febrile neutropenia: case report and systematic review. Travel Med Infect Dis. 2022 Mar 7;47:102305.Full text  Abstract

643. Fistera D, Härtl A, Pabst D, et al. What about the others: differential diagnosis of COVID-19 in a German emergency department. BMC Infect Dis. 2021 Sep 17;21(1):969.Full text  Abstract

644. National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Feb 2024 [internet publication].Full text

645. World Health Organization. Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022. Jul 2022 [internet publication].Full text

646. UK Health Security Agency. People with symptoms of a respiratory infection including COVID-19. Jun 2022 [internet publication].Full text

647. Centers for Disease Control and Prevention. CDC streamlines COVID-19 guidance to help the public better protect themselves and understand their risk. Aug 2022 [internet publication].Full text

648. Kwon KT, Ko JH, Shin H, et al. Drive-through screening center for COVID-19: a safe and efficient screening system against massive community outbreak. J Korean Med Sci. 2020 Mar 23;35(11):e123.Full text  Abstract

649. Medicines and Healthcare products Regulatory Agency. Don’t rely on temperature screening products for detection of coronavirus (COVID-19), says MHRA. Jul 2020 [internet publication].Full text

650. Aggarwal N, Garg M, Dwarakanathan V, et al. Diagnostic accuracy of non-contact infrared thermometers and thermal scanners: a systematic review and meta-analysis. J Travel Med. 2020 Dec 23;27(8):taaa193.Full text  Abstract

651. Khan DS, Saultry MB, Adams DS, et al. Comparative accuracy testing of non-contact infrared thermometers and temporal artery thermometers in an adult hospital setting. Am J Infect Control. 2021 May;49(5):597-602.Full text  Abstract

652. Centers for Disease Control and Prevention. Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic. Mar 2024 [internet publication].Full text

653. American Academy of Pediatrics. COVID-19 testing guidance. Dec 2022 [internet publication].Full text

654. Infectious Diseases Society of America. Infectious Diseases Society of America guidelines on infection prevention for healthcare personnel caring for patients with suspected or known COVID-19. Nov 2021 [internet publication].Full text

655. UK Health Security Agency. Coronavirus (COVID-19): guidance. Feb 2024 [internet publication].Full text

656. European Society of Clinical Microbiology and Infectious Diseases. ESCMID COVID-19 guidelines. Nov 2023 [internet publication].Full text

657. World Health Organization. Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance. Aug 2020 [internet publication].Full text

658. Suter F, Consolaro E, Pedroni S, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine. 2021 Jun 9:100941.Full text  Abstract

659. Crotty BH, Dong Y, Laud P, et al. Hospitalization outcomes among patients with COVID-19 undergoing remote monitoring. JAMA Netw Open. 2022 Jul 1;5(7):e2221050.Full text  Abstract

660. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020 Jun 23;323(24):2512-4.Full text  Abstract

661. Nag AK, Saltagi AK, Saltagi MZ, et al. Management of post-infectious anosmia and hyposmia: a systematic review. Ann Otol Rhinol Laryngol. 2022 Aug 12:34894221118186. Abstract

662. Webster KE, O'Byrne L, MacKeith S, et al. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877.Full text  Abstract

663. O'Byrne L, Webster KE, MacKeith S, et al. Interventions for the treatment of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013876.Full text  Abstract

664. Asvapoositkul V, Samuthpongtorn J, Aeumjaturapat S, et al. Therapeutic options of post-COVID-19 related olfactory dysfunction: a systematic review and meta-analysis. Rhinology. 2023 Feb 1;61(1):2-11.Full text  Abstract

665. Agarwal A, Rochwerg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. BMJ. 2020 Sep 4;370:m3379.Full text  Abstract

666. Agarwal A, Hunt BJ, Stegemann M, et al. Update to living WHO guideline on drugs for covid-19. BMJ. 2023 Nov 9;383:2622. Abstract

667. National Institute for Health and Care Excellence. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. Mar 2024 [internet publication].Full text

668. Cruciani M, Pati I, Masiello F, et al. SARS-CoV-2 infection rebound among patients receiving antiviral agents, convalescent plasma, or no treatment: a systematic review with meta-analysis. Blood Transfus. 2024 May 27 [Epub ahead of print].Full text  Abstract

669. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022 Apr 14;386(15):1397-408.Full text  Abstract

670. Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19. N Engl J Med. 2024 Apr 4;390(13):1186-95.Full text  Abstract

671. Tian H, Yang C, Song T, et al. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID-19: an updated meta-analysis and trial sequential analysis. Rev Med Virol. 2023 Sep;33(5):e2473. Abstract

672. Li H, Xiang H, He B, et al. Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: a systematic review and meta-analysis. J Glob Health. 2023 Jul 21;13:06032.Full text  Abstract

673. Zhu CT, Yin JY, Chen XH, et al. Appraisal of evidence reliability and applicability of Paxlovid as treatment for SARS-COV-2 infection: a systematic review. Rev Med Virol. 2023 Aug 14:e2476. Abstract

674. Reis S, Metzendorf MI, Kuehn R, et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395.Full text  Abstract

675. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509-20.Full text  Abstract

676. Butler CC, Hobbs FDR, Gbinigie OA, et al. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023 Jan 28;401(10373):281-93.Full text  Abstract

677. Tian F, Feng Q, Chen Z. Efficacy and safety of molnupiravir treatment for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2023 Aug;62(2):106870.Full text  Abstract

678. Malin JJ, Weibel S, Gruell H, et al. Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis. J Antimicrob Chemother. 2023 Jul 5;78(7):1586-98.Full text  Abstract

679. Benaicha K, Khenhrani RR, Veer M, et al. Efficacy of molnupiravir for the treatment of mild or moderate COVID-19 in adults: a meta-analysis. Cureus. 2023 May;15(5):e38586.Full text  Abstract

680. Sun M, Lai H, Huang J, et al. Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients. J Antimicrob Chemother. 2023 Sep 5;78(9):2131-9.Full text  Abstract

681. Sanderson T, Hisner R, Donovan-Banfield I, et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature. 2023 Nov;623(7987):594-600. Abstract

682. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022 Jan 27;386(4):305-15.Full text  Abstract

683. Amani B, Akbarzadeh A, Amani B, et al. Comparative efficacy and safety of nirmatrelvir/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis. J Med Virol. 2023 Jun;95(6):e28889. Abstract

684. National Institute for Health and Care Excellence. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19. May 2024 [internet publication].Full text

685. US Food and Drug Administration. FDA announces bebtelovimab is not currently authorized in any US region. Nov 2022 [internet publication].Full text

686. Hirsch C, Park YS, Piechotta V, et al. SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19. Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945.Full text  Abstract

687. Hernandez AV, Piscoya A, Pasupuleti V, et al. Beneficial and harmful effects of monoclonal antibodies for the treatment and prophylaxis of COVID-19: systematic review and meta-analysis. Am J Med. 2022 Jul 23;135(11):1349-61.Full text  Abstract

688. Barnes GD, Burnett A, Allen A, et al. Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis. 2022 Aug;54(2):197-210.Full text  Abstract

689. Santos BC, Flumignan RL, Civile VT, et al. Prophylactic anticoagulants for non-hospitalised people with COVID-19. Cochrane Database Syst Rev. 2023 Aug 16;8(8):CD015102.Full text  Abstract

690. Fischer AL, Messer S, Riera R, et al. Antiplatelet agents for the treatment of adults with COVID-19. Cochrane Database Syst Rev. 2023 Jul 25;7(7):CD015078.Full text  Abstract

691. Department of Health and Social Care. Higher-risk patients eligible for COVID-19 treatments: independent advisory group report. Sep 2023 [internet publication].Full text

692. Alimohamadi Y, Yekta EM, Sepandi M, et al. Hospital length of stay for COVID-19 patients: a systematic review and meta-analysis. Multidiscip Respir Med. 2022 Jan 12;17(1):856.Full text  Abstract

693. British Geriatrics Society; Boreskie K, Conroy S. COVID-19: frailty scores and outcomes in older people. Jun 2021 [internet publication].Full text

694. Rottler M, Ocskay K, Sipos Z, et al. Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis. Ann Intensive Care. 2022 Feb 20;12(1):17.Full text  Abstract

695. Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021 Mar-Apr;93:104324.Full text  Abstract

696. Subramaniam A, Shekar K, Afroz A, et al. Frailty and mortality associations in patients with COVID-19: a systematic review and meta-analysis. Intern Med J. 2022 May;52(5):724-39.Full text  Abstract

697. Cosco TD, Best J, Davis D, et al. What is the relationship between validated frailty scores and mortality for adults with COVID-19 in acute hospital care? A systematic review. Age Ageing. 2021 May 5;50(3):608-16.Full text  Abstract

698. Centre for Evidence-Based Medicine; Allsop M, Ziegler L, Fu Y, et al. Is oxygen an effective treatment option to alleviate the symptoms of breathlessness for patients dying with COVID-19 and what are the potential harms? May 2020 [internet publication].Full text

699. Alhazzani W, Evans L, Alshamsi F, et al. Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021 Mar 1;49(3):e219-34.Full text  Abstract

700. Weatherald J, Parhar KKS, Al Duhailib Z, et al. Efficacy of awake prone positioning in patients with covid-19 related hypoxemic respiratory failure: systematic review and meta-analysis of randomized trials. BMJ. 2022 Dec 7;379:e071966.Full text  Abstract

701. Mojoli F, Mongodi S, Orlando A, et al. Our recommendations for acute management of COVID-19. Crit Care. 2020 May 8;24(1):207.Full text  Abstract

702. Centre for Evidence-Based Medicine; Jones L, Candy B, Roberts N, et al. How can healthcare workers adapt non-pharmacological treatment – whilst maintaining safety – when treating people with COVID-19 and delirium? May 2020 [internet publication].Full text

703. UK Health Security Agency. Mouth care for hospitalised patients with confirmed or suspected COVID-19. Aug 2020 [internet publication].Full text

704. Zeng J, Liu F, Wang Y, et al. The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022 Feb 3;54:107-10.Full text  Abstract

705. Flumignan RL, Civile VT, Tinôco JDS, et al. Anticoagulants for people hospitalised with COVID-19. Cochrane Database Syst Rev. 2022 Mar 4;(3):CD013739.Full text  Abstract

706. Moonla C, Sosothikul D, Chiasakul T, et al. Anticoagulation and in-hospital mortality from coronavirus disease 2019: a systematic review and meta-analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999.Full text  Abstract

707. American Society Of Hematology. COVID-19 and VTE/anticoagulation: frequently asked questions. Feb 2022 [internet publication].Full text

708. Alsagaff MY, Mulia EPB, Maghfirah I, et al. Low molecular weight heparin is associated with better outcomes than unfractionated heparin for thromboprophylaxis in hospitalized COVID-19 patients: a meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2022 Nov 17;8(8):909-18.Full text  Abstract

709. Dai MF, Xin WX, Kong S, et al. Effectiveness and safety of extended thromboprophylaxis in post-discharge patients with COVID-19: a systematic review and meta-analysis. Thromb Res. 2023 Jan;221:105-12.Full text  Abstract

710. Langford BJ, So M, Raybardhan S, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021 Apr;27(4):520-31.Full text  Abstract

711. Wagner C, Griesel M, Mikolajewska A, et al. Systemic corticosteroids for the treatment of COVID‐19: equity‐related analyses and update on evidence. Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963.Full text  Abstract

712. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020 Jul 30;370:m2980.Full text  Abstract

713. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Update to living systematic review on drug treatments for covid-19. BMJ. 2022 Jul 13;378:o1717.Full text  Abstract

714. Pitre T, Su J, Mah J, et al. Higher versus lower dose corticosteroids for severe to critical COVID-19: a systematic review and dose-response meta-analysis. Ann Am Thorac Soc. 2023 Apr;20(4):596-604.Full text  Abstract

715. RECOVERY Collaborative Group. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2023 May 6;401(10387):1499-507.Full text  Abstract

716. Ssentongo P, Yu N, Voleti N, et al. Optimal duration of systemic corticosteroids in coronavirus disease 2019 treatment: a systematic review and meta-analysis. Open Forum Infect Dis. 2023 Mar;10(3):ofad105.Full text  Abstract

717. Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962.Full text  Abstract

718. Nevalainen OPO, Horstia S, Laakkonen S, et al. Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun. 2022 Oct 18;13(1):6152.Full text  Abstract

719. Wan EYF, Yan VKC, Mok AHY, et al. Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023 Apr;176(4):505-14.Full text  Abstract

720. Ghosn L, Assi R, Evrenoglou T, et al. Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013881.Full text  Abstract

721. Zeraatkar D, Cusano E, Martínez JPD, et al. Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. BMJ Med. 2022 Feb 28;1(1):e000036.Full text  Abstract

722. Kramer A, Prinz C, Fichtner F, et al. Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209.Full text  Abstract

723. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: a rapid systematic review. Palliat Med. 2021 Jun;35(6):1099-107.Full text  Abstract

724. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ. 2020 May 29;369:m1996.Full text  Abstract

725. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the Seattle region: case series. N Engl J Med. 2020 May 21;382(21):2012-22.Full text  Abstract

726. Schmid B, Griesel M, Fischer AL, et al. Awake prone positioning, high-flow nasal oxygen and non-invasive ventilation as non-invasive respiratory strategies in COVID-19 acute respiratory failure: a systematic review and meta-analysis. J Clin Med. 2022 Jan 13;11(2):391.Full text  Abstract

727. Weerakkody S, Arina P, Glenister J, et al. Non-invasive respiratory support in the management of acute COVID-19 pneumonia: considerations for clinical practice and priorities for research. Lancet Respir Med. 2022 Feb;10(2):199-213.Full text  Abstract

728. Schünemann HJ, Khabsa J, Solo K, et al. Ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2020 Aug 4;173(3):204-16.Full text  Abstract

729. Ute Muti-Schüenemann GE, Szczeklik W, Solo K, et al. Update alert 3: ventilation techniques and risk for transmission of coronavirus disease, including COVID-19. Ann Intern Med. 2022 Jan;175(1):W6-7.Full text  Abstract

730. Glenardi G, Chriestya F, Oetoro BJ, et al. Comparison of high-flow nasal oxygen therapy and noninvasive ventilation in COVID-19 patients: a systematic review and meta-analysis. Acute Crit Care. 2022 Feb;37(1):71-83.Full text  Abstract

731. Beran A, Srour O, Malhas SE, et al. High-flow nasal cannula oxygen versus non-invasive ventilation in subjects with COVID-19: a systematic review and meta-analysis of comparative studies. Respir Care. 2022 Sep;67(9):1177-89.Full text  Abstract

732. Li Y, Li C, Chang W, et al. High-flow nasal cannula reduces intubation rate in patients with COVID-19 with acute respiratory failure: a meta-analysis and systematic review. BMJ Open. 2023 Mar 30;13(3):e067879.Full text  Abstract

733. Perkins GD, Ji C, Connolly BA, et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. JAMA. 2022 Feb 8;327(6):546-58.Full text  Abstract

734. Arabi YM, Aldekhyl S, Al Qahtani S, et al. Effect of helmet noninvasive ventilation vs usual respiratory support on mortality among patients with acute hypoxemic respiratory failure due to COVID-19: the HELMET-COVID randomized clinical trial. JAMA. 2022 Sep 20;328(11):1063-72.Full text  Abstract

735. Frat JP, Quenot JP, Badie J, et al. Effect of high-flow nasal cannula oxygen vs standard oxygen therapy on mortality in patients with respiratory failure due to COVID-19: the SOHO-COVID randomized clinical trial. JAMA. 2022 Sep 27;328(12):1212-22.Full text  Abstract

736. Ospina-Tascón GA, Calderón-Tapia LE, García AF, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021 Dec 7;326(21):2161-71. Abstract

737. Winslow RL, Zhou J, Windle EF, et al. SARS-CoV-2 environmental contamination from hospitalised patients with COVID-19 receiving aerosol-generating procedures. Thorax. 2022 Mar;77(3):259-67.Full text  Abstract

738. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J. 2020 May 14;55(5):2000892.Full text  Abstract

739. Zhang MX, Lilien TA, van Etten-Jamaludin FS, et al. Generation of aerosols by noninvasive respiratory support modalities: a systematic review and meta-analysis. JAMA Netw Open. 2023 Oct 2;6(10):e2337258.Full text  Abstract

740. Elsayed HH, Hassaballa AS, Ahmed TA, et al. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0252760.Full text  Abstract

741. Xourgia E, Katsaros DE, Xixi NA, et al. Mortality of intubated patients with COVID-19 during first and subsequent waves: a meta-analysis involving 363,660 patients from 43 countries. Expert Rev Respir Med. 2022 Oct;16(10):1101-8. Abstract

742. Xixi NA, Kremmydas P, Xourgia E, et al. Association between timing of intubation and clinical outcomes of critically ill patients: a meta-analysis. J Crit Care. 2022 May 16;71:154062. Abstract

743. Lee HJ, Kim J, Choi M, et al. Early intubation and clinical outcomes in patients with severe COVID-19: a systematic review and meta-analysis. Eur J Med Res. 2022 Nov 3;27(1):226.Full text  Abstract

744. Gattinoni L, Coppola S, Cressoni M, et al. Covid-19 does not lead to a "typical" acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 May 15;201(10):1299-300.Full text  Abstract

745. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care. 2020 Apr 16;24(1):154.Full text  Abstract

746. Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-102.Full text  Abstract

747. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Jun 9;323(22):2329-30.Full text  Abstract

748. Rello J, Storti E, Belliato M, et al. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020 May 21;55(5):2001028.Full text  Abstract

749. Tsolaki V, Siempos I, Magira E, et al. PEEP levels in COVID-19 pneumonia. Crit Care. 2020 Jun 6;24(1):303.Full text  Abstract

750. Bos LD, Paulus F, Vlaar APJ, et al. Subphenotyping acute respiratory distress syndrome in patients with COVID-19: consequences for ventilator management. Ann Am Thorac Soc. 2020 Sep;17(9):1161-3.Full text  Abstract

751. Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020 May 18;:1-2.Full text  Abstract

752. Reddy MP, Subramaniam A, Chua C, et al. Respiratory system mechanics, gas exchange, and outcomes in mechanically ventilated patients with COVID-19-related acute respiratory distress syndrome: a systematic review and meta-analysis. Lancet Respir Med. 2022 Dec;10(12):1178-88.Full text  Abstract

753. Rice TW, Janz DR. In defense of evidence-based medicine for the treatment of COVID-19 ARDS. Ann Am Thorac Soc. 2020 Jul;17(7):787-9.Full text  Abstract

754. Dondorp AM, Hayat M, Aryal D, et al. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020 Jun;102(6):1191-7.Full text  Abstract

755. Carsetti A, Damia Paciarini A, Marini B, et al. Prolonged prone position ventilation for SARS-CoV-2 patients is feasible and effective. Crit Care. 2020 May 15;24(1):225.Full text  Abstract

756. Fayed M, Maroun W, Elnahla A, et al. Prone vs. supine position ventilation in intubated COVID-19 patients: a systematic review and meta-analysis. Cureus. 2023 May;15(5):e39636.Full text  Abstract

757. Khokher W, Malhas SE, Beran A, et al. Inhaled pulmonary vasodilators in COVID-19 infection: a systematic review and meta-analysis. J Intensive Care Med. 2022 Oct;37(10):1370-82.Full text  Abstract

758. Urner M, Barnett AG, Bassi GL, et al. Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ. 2022 May 4;377:e068723.Full text  Abstract

759. Bertini P, Guarracino F, Falcone M, et al. ECMO in COVID-19 patients: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt A):2700-6.Full text  Abstract

760. Ling RR, Ramanathan K, Sim JJL, et al. Evolving outcomes of extracorporeal membrane oxygenation during the first 2 years of the COVID-19 pandemic: a systematic review and meta-analysis. Crit Care. 2022 May 23;26(1):147.Full text  Abstract

761. Watanabe A, Yasuhara J, Karube T, et al. Extracorporeal membrane oxygenation in children with COVID-19: a systematic review and meta-analysis. Pediatr Crit Care Med. 2023 May 1;24(5):406-16.Full text  Abstract

762. Tran A, Fernando SM, Rochwerg B, et al. Prognostic factors associated with mortality among patients receiving venovenous extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. Lancet Respir Med. 2023 Mar;11(3):235-44.Full text  Abstract

763. Kannapadi NV, Jami M, Premraj L, et al. Neurological complications in COVID-19 patients with ECMO support: a systematic review and meta-analysis. Heart Lung Circ. 2022 Feb;31(2):292-8.Full text  Abstract

764. Li CMF, Densy Deng X, Ma YF, et al. Neurologic complications of patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis. Crit Care Explor. 2023 Apr;5(4):e0887.Full text  Abstract

765. Jin Y, Zhang Y, Liu J, et al. Thrombosis and bleeding in patients with COVID-19 requiring extracorporeal membrane oxygenation: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2023 Feb;7(2):100103.Full text  Abstract

766. Zhang S, Li Y, Liu G, et al. Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis. Thromb J. 2021 Nov 24;19(1):91.Full text  Abstract

767. Bonfim LCMG, Guerini IS, Zambon MG, et al. Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. J Crit Care. 2023 Oct;77:154344.Full text  Abstract

768. Andreas M, Piechotta V, Skoetz N, et al. Interventions for palliative symptom control in COVID-19 patients. Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD015061.Full text  Abstract

769. Nana M, Hodson K, Lucas N, et al. Diagnosis and management of covid-19 in pregnancy. BMJ. 2022 Apr 26;377:e069739.Full text  Abstract

770. Girolamo RD, Khalil A, Rizzo G, et al. Systematic review and critical evaluation of quality of clinical practice guidelines on the management of SARS-CoV-2 infection in pregnancy. Am J Obstet Gynecol MFM. 2022 Sep;4(5):100654.Full text  Abstract

771. Garneau WM, Jones-Beatty K, Ufua MO, et al. Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for acute SARS-CoV-2 infection. JAMA Netw Open. 2022 Nov 1;5(11):e2244141.Full text  Abstract

772. Izcovich A, Siemieniuk RA, Bartoszko JJ, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022 Mar 2;12(3):e048502.Full text  Abstract

773. Devgun JM, Zhang R, Brent J, et al. Identification of bradycardia following remdesivir administration through the US Food and Drug Administration American College of Medical Toxicology COVID-19 toxic pharmacovigilance project. JAMA Netw Open. 2023 Feb 1;6(2):e2255815.Full text  Abstract

774. Ishisaka Y, Aikawa T, Malik A, et al. Association of remdesivir use with bradycardia: a systematic review and meta-analysis. J Med Virol. 2023 Aug;95(8):e29018. Abstract

775. Zhuang W, Xu J, Wu Y, et al. Post-marketing safety concerns with nirmatrelvir: a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Br J Clin Pharmacol. 2023 Sep;89(9):2830-42. Abstract

776. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143-63.Full text  Abstract

777. Vlaar APJ, Witzenrath M, van Paassen P, et al. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022 Dec;10(12):1137-46.Full text  Abstract

778. US Food and Drug Administration. FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19. Apr 2023 [internet publication].Full text

779. Kyriazopoulou E, Huet T, Cavalli G, et al. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021 Oct;3(10):e690-7.Full text  Abstract

780. Barkas F, Ntekouan SF, Kosmidou M, et al. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis. Rheumatology (Oxford). 2021 Dec 1;60(12):5527-37.Full text  Abstract

781. Somagutta MKR, Lourdes Pormento MK, Hamid P, et al. The safety and efficacy of anakinra, an interleukin-1 antagonist in severe cases of COVID-19: a systematic review and meta-analysis. Infect Chemother. 2021 Jun;53(2):221-37.Full text  Abstract

782. Davidson M, Menon S, Chaimani A, et al. Interleukin-1 blocking agents for treating COVID-19. Cochrane Database Syst Rev. 2022 Jan 26;(1):CD015308.Full text  Abstract

783. Mikolajewska A, Fischer AL, Piechotta V, et al. Colchicine for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 18;(10):CD015045.Full text  Abstract

784. Estcourt LJ, Cohn CS, Pagano MB, et al. Clinical practice guidelines from the association for the advancement of blood and biotherapies (AABB): COVID-19 convalescent plasma. Ann Intern Med. 2022 Sep;175(9):1310-21.Full text  Abstract

785. Iannizzi C, Chai KL, Piechotta V, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600.Full text  Abstract

786. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. BMJ. 2021 Sep 23;374:n2231.Full text  Abstract

787. Janiaud P, Axfors C, Schmitt AM, et al. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. JAMA. 2021 Mar 23;325(12):1185-95.Full text  Abstract

788. Gupta T, Kannan S, Kalra B, et al. Systematic review and meta-analysis of randomised controlled trials testing the safety and efficacy of convalescent plasma in the treatment of coronavirus disease 2019 (COVID-19): evidence-base for practise and implications for research. Transfus Med. 2021 Dec;31(6):409-20.Full text  Abstract

789. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis. Mayo Clin Proc. 2021 May;96(5):1262-75.Full text  Abstract

790. Wardhani SO, Fajar JK, Wulandari L, et al. Association between convalescent plasma and the risk of mortality among patients with COVID-19: a meta-analysis. F1000Res. 2021 Feb 3;10:64.Full text  Abstract

791. Kloypan C, Saesong M, Sangsuemoon J, et al. Convalescent plasma for COVID-19: a meta-analysis of clinical trials and real-world evidence. Eur J Clin Invest. 2021 Aug 10:e13663.Full text  Abstract

792. Axfors C, Janiaud P, Schmitt AM, et al. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infect Dis. 2021 Nov 20;21(1):1170.Full text  Abstract

793. Senefeld JW, Franchini M, Mengoli C, et al. COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis. JAMA Netw Open. 2023 Jan 3;6(1):e2250647.Full text  Abstract

794. Levine AC, Fukuta Y, Huaman MA, et al. Coronavirus disease 2019 convalescent plasma outpatient therapy to prevent outpatient hospitalization: a meta-analysis of individual participant data from 5 randomized trials. Clin Infect Dis. 2023 Jun 16;76(12):2077-86.Full text  Abstract

795. Kimber C, Valk SJ, Chai KL, et al. Hyperimmune immunoglobulin for people with COVID-19. Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD015167.Full text  Abstract

796. Xiang HR, Cheng X, Li Y, et al. Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): a meta-analysis. Int Immunopharmacol. 2021 Jul;96:107732.Full text  Abstract

797. Liu X, Zhang Y, Lu L, et al. Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis. Front Immunol. 2023 Jan 23;14:1116738.Full text  Abstract

798. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022 Mar;10(3):237-46.Full text  Abstract

799. Cremer PC, Abbate A, Hudock K, et al. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021 Jun;3(6):e410-8.Full text  Abstract

800. Xi AR, Luo YJ, Guan JT, et al. Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in COVID-19 patients: a meta-analysis. Inflammopharmacology. 2023 Feb;31(1):275-85.Full text  Abstract

801. Li Y, Wei Z, Ma X, et al. Efficacy and safety of mesenchymal stromal cells therapy for COVID-19 infection: a systematic review and meta-analysis. Curr Stem Cell Res Ther. 2023;18(1):143-52. Abstract

802. Kirkham AM, Bailey AJM, Monaghan M, et al. Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: a framework for accelerated synthesis of trial evidence for rapid approval - FASTER approval. Stem Cells Transl Med. 2022 Jul 20;11(7):675-87.Full text  Abstract

803. Yao W, Dong H, Qi J, et al. Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2022 Sep;51:101545.Full text  Abstract

804. WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19: interim WHO Solidarity trial results. N Engl J Med. 2021 Feb 11;384(6):497-511.Full text  Abstract

805. Feld JJ, Kandel C, Biondi MJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021 May;9(5):498-510.Full text  Abstract

806. Reis G, Moreira Silva EAS, Medeiros Silva DC, et al. Early treatment with pegylated interferon lambda for Covid-19. N Engl J Med. 2023 Feb 9;388(6):518-28.Full text  Abstract

807. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun;178:104787.Full text  Abstract

808. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 Jun 21;28(4):e434-60.Full text  Abstract

809. Kory P, Meduri GU, Varon J, et al. Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Am J Ther. 2021 Apr 22;28(3):e299-318.Full text  Abstract

810. Zein AFMZ, Sulistiyana CS, Raffaelo WM, et al. Ivermectin and mortality in patients with COVID-19: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021 Jun 27;15(4):102186.Full text  Abstract

811. Kow CS, Merchant HA, Mustafa ZU, et al. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep. 2021 Oct;73(5):1473-9.Full text  Abstract

812. Padhy BM, Mohanty RR, Das S, et al. Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.Full text  Abstract

813. Azeez TA, Lakoh S, Adeleke AA, et al. Chemoprophylaxis against COVID-19 among health-care workers using ivermectin in low- and middle-income countries: a systematic review and meta-analysis. Indian J Pharmacol. 2021 Nov-Dec;53(6):493-8.Full text  Abstract

814. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for the treatment of coronavirus disease 2019: a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2022 Mar 23;74(6):1022-9.Full text  Abstract

815. Deng J, Zhou F, Ali S, et al. Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM. 2021 Dec 20;114(10):721-32.Full text  Abstract

816. Bitterman A, Martins CP, Cices A, et al. Comparison of trials using ivermectin for COVID-19 between regions with high and low prevalence of strongyloidiasis: a meta-analysis. JAMA Netw Open. 2022 Mar 1;5(3):e223079.Full text  Abstract

817. Marcolino MS, Meira KC, Guimarães NS, et al. Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis. 2022 Jul 23;22(1):639.Full text  Abstract

818. Popp M, Reis S, Schießer S, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017.Full text  Abstract

819. Nyirenda JL, Sofroniou M, Toews I, et al. Fluvoxamine for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Sep 14;9(9):CD015391.Full text  Abstract

820. Guo CM, Harari O, Chernecki C, et al. Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials. Am J Trop Med Hyg. 2022 Mar 9;106(5):1315-20.Full text  Abstract

821. European Medicines Agency. EMA reviewing data on sabizabulin for COVID-19. Jul 2022 [internet publication].Full text

822. Barnette KG, Gordon MS, Rodriguez D, et al. Oral sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis. NEJM Evid. 2022 Sep;1(9):EVIDoa2200145.Full text  Abstract

823. Cao Z, Gao W, Bao H, et al. VV116 versus nirmatrelvir-ritonavir for oral treatment of Covid-19. N Engl J Med. 2023 Feb 2;388(5):406-17.Full text  Abstract

824. Fan X, Dai X, Ling Y, et al. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study. Lancet Infect Dis. 2024 Feb;24(2):129-39.Full text  Abstract

825. McCarthy MW. Ensitrelvir as a potential treatment for COVID-19. Expert Opin Pharmacother. 2022 Dec;23(18):1995-8. Abstract

826. Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (phase 3 part). Medicine (Baltimore). 2023 Feb 22;102(8):e33024.Full text  Abstract

827. Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and safety of 5-day oral ensitrelvir for patients with mild to moderate COVID-19: the SCORPIO-SR randomized clinical trial. JAMA Netw Open. 2024 Feb 5;7(2):e2354991.Full text  Abstract

828. ClinicalTrials.gov. Study to access the efficacy and safety of STI-1558 in adult subjects with mild or moderate (COVID-19). May 2024 [internet publication].Full text

829. Cao B, Wang Y, Lu H, et al. Oral simnotrelvir for adult patients with mild-to-moderate Covid-19. N Engl J Med. 2024 Jan 18;390(3):230-41.Full text  Abstract

830. ClinicalTrials.gov. SUNRISE-3: efficacy and safety of bemnifosbuvir in high-risk outpatients with COVID-19. Apr 2024 [internet publication].Full text

831. Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev. 2022 Mar 9;(3):CD015125.Full text  Abstract

832. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Jan 8;399(10320):143-51.Full text  Abstract

833. Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022 Dec;10(12):1160-8.Full text  Abstract

834. Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022 Dec;10(12):1169-77.Full text  Abstract

835. Su W, Miao H, Guo Z, et al. Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: a meta-analysis. Front Pharmacol. 2022 Oct 5;13:989903.Full text  Abstract

836. Wijaya I, Andhika R, Huang I, et al. The effects of aspirin on the outcome of COVID-19: a systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021 Oct-Dec;12:100883.Full text  Abstract

837. Popp M, Stegemann M, Riemer M, et al. Antibiotics for the treatment of COVID-19. Cochrane Database Syst Rev. 2021 Oct 22;(10):CD015025.Full text  Abstract

838. Butler CC, Yu LM, Dorward J, et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respir Med. 2021 Sep;9(9):1010-20.Full text  Abstract

839. Jolliffe DA, Camargo CA Jr, Sluyter JD, et al. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials. Lancet Diabetes Endocrinol. 2021 May;9(5):276-92.Full text  Abstract

840. Boretti A, Banik BK. Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome. PharmaNutrition. 2020 Apr 21:100190.Full text  Abstract

841. Abioye AI, Bromage S, Fawzi W. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis. BMJ Glob Health. 2021 Jan;6(1):e003176.Full text  Abstract

842. Bhowmik KK, Barek MA, Aziz MA, et al. Impact of high-dose vitamin C on the mortality, severity, and duration of hospital stay in COVID-19 patients: a meta-analysis. Health Sci Rep. 2022 Sep;5(5):e762.Full text  Abstract

843. Olczak-Pruc M, Swieczkowski D, Ladny JR, et al. Vitamin C supplementation for the treatment of COVID-19: a systematic review and meta-analysis. Nutrients. 2022 Oct 10;14(19):4217.Full text  Abstract

844. Rawat D, Roy A, Maitra S, et al. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Syndr. 2021 Oct 28;15(6):102324.Full text  Abstract

845. Kwak SG, Choo YJ, Chang MC. The effectiveness of high-dose intravenous vitamin C for patients with coronavirus disease 2019: a systematic review and meta-analysis. Complement Ther Med. 2021 Dec 22;64:102797.Full text  Abstract

846. Stroehlein JK, Wallqvist J, Iannizzi C, et al. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;(5):CD015043.Full text  Abstract

847. Pal R, Banerjee M, Bhadada SK, et al. Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis. J Endocrinol Invest. 2022 Jan;45(1):53-68.Full text  Abstract

848. Szarpak L, Filipiak KJ, Gasecka A, et al. Vitamin D supplementation to treat SARS-CoV-2 positive patients: evidence from meta-analysis. Cardiol J. 2022;29(2):188-96.Full text  Abstract

849. Tentolouris N, Samakidou G, Eleftheriadou I, et al. The effect of vitamin D supplementation on mortality and intensive care unit admission of COVID-19 patients: a systematic review, meta-analysis and meta-regression. Diabetes Metab Res Rev. 2022 May;38(4):e3517.Full text  Abstract

850. Shah K, Varna VP, Sharma U, et al. Does vitamin D supplementation reduce COVID-19 severity? A systematic review. QJM. 2022 Oct 25;115(10):665-72.Full text  Abstract

851. Hosseini B, El Abd A, Ducharme FM. Effects of vitamin D supplementation on COVID-19 related outcomes: a systematic review and meta-analysis. Nutrients. 2022 May 20;14(10):2134.Full text  Abstract

852. D'Ecclesiis O, Gavioli C, Martinoli C, et al. Vitamin D and SARS-CoV2 infection, severity and mortality: a systematic review and meta-analysis. PLoS One. 2022 Jul 6;17(7):e0268396.Full text  Abstract

853. Tabatabaeizadeh SA. Zinc supplementation and COVID-19 mortality: a meta-analysis. Eur J Med Res. 2022 May 23;27(1):70.Full text  Abstract

854. Rheingold SZ, Raval C, Gordon AM, et al. Zinc supplementation associated with a decrease in mortality in COVID-19 patients: a meta-analysis. Cureus. 2023 Jun;15(6):e40231.Full text  Abstract

855. Yue HY, Zeng J, Wang Y, et al. Efficacy of omega-3 fatty acids for hospitalized COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr. 2023 Sep;32(3):308-20.Full text  Abstract

856. Neris Almeida Viana S, do Reis Santos Pereira T, de Carvalho Alves J, et al. Benefits of probiotic use on COVID-19: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022 Sep 30:1-13. Abstract

857. Tian Y, Ran H, Wen X, et al. Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis. Front Nutr. 2023 May 22;10:1179432.Full text  Abstract

858. Sohail A, Cheema HA, Mithani MS, et al. Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis. Front Nutr. 2023;10:1274122.Full text  Abstract

859. Lan SH, Lee HZ, Chao CM, et al. Efficacy of melatonin in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. J Med Virol. 2022 May;94(5):2102-7.Full text  Abstract

860. Faridzadeh A, Tabashiri A, Miri HH, et al. The role of melatonin as an adjuvant in the treatment of COVID-19: a systematic review. Heliyon. 2022 Oct;8(10):e10906.Full text  Abstract

861. Molina-Carballo A, Palacios-López R, Jerez-Calero A, et al. Protective effect of melatonin administration against SARS-CoV-2 infection: a systematic review. Curr Issues Mol Biol. 2021 Dec 22;44(1):31-45.Full text  Abstract

862. Wang XC, Wu GL, Cai YF, et al. The safety and efficacy of melatonin in the treatment of COVID-19: a systematic review and meta-analysis. Medicine (Baltimore). 2022 Sep 30;101(39):e30874.Full text  Abstract

863. Roach A, Chikwe J, Catarino P, et al. Lung transplantation for Covid-19-related respiratory failure in the United States. N Engl J Med. 2022 Mar 24;386(12):1187-8.Full text  Abstract

864. Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant. JAMA. 2022 Feb 15;327(7):652-61.Full text  Abstract

865. Centers for Disease Control and Prevention. Interim clinical considerations for use of COVID-19 vaccines in the United States. Apr 2024 [internet publication].Full text

866. Centers for Disease Control and Prevention. Healthcare workers: information on COVID-19. Mar 2024 [internet publication].Full text

867. American Academy of Pediatrics. COVID-19 interim guidance. Feb 2023 [internet publication].Full text

868. World Health Organization. COVID-19 outbreak toolbox. Sep 2022 [internet publication].Full text

869. UK Health Security Agency. COVID-19: the green book, chapter 14a. Apr 2024 [internet publication].Full text

870. Royal College of Obstetricians and Gynaecologists. Coronavirus (COVID-19) infection in pregnancy: information for healthcare professionals. Dec 2022 [internet publication].Full text

871. Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism in COVID-19. Dec 2021 [internet publication].Full text

872. Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021 Apr 15;57(4):2100048.Full text  Abstract

873. All India Institute Of Medical Sciences; Indian Council of Medical Research. Clinical guidance for management of adult COVID-19 patients. Mar 2023 [internet publication].Full text

874. White H, McDonald SJ, Barber B, et al. Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce. Med J Aust. 2022 Oct 3;217(7):368-78.Full text  Abstract

875. Department of Health Australia. Coronavirus disease 2019 (COVID-19). Oct 2022 [internet publication].Full text

876. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 May;46(5):846-8.Full text  Abstract

877. Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med. 2020 Nov;14(11):1149-63.Full text  Abstract

878. Dmytriw AA, Chibbar R, Chen PPY, et al. Outcomes of acute respiratory distress syndrome in COVID-19 patients compared to the general population: a systematic review and meta-analysis. Expert Rev Respir Med. 2021 Oct;15(10):1347-54.Full text  Abstract

879. de la Calle C, Lalueza A, Mancheño-Losa M, et al. Impact of viral load at admission on the development of respiratory failure in hospitalized patients with SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 Jun;40(6):1209-16.Full text  Abstract

880. Elezkurtaj S, Greuel S, Ihlow J, et al. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263.Full text  Abstract

881. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020 Sep;188:109890.Full text  Abstract

882. Sumner MW, Kanngiesser A, Lotfali-Khani K, et al. Severe outcomes associated with SARS-CoV-2 infection in children: a systematic review and meta-analysis. Front Pediatr. 2022 Jun 9;10:916655.Full text  Abstract

883. Justino DCP, Silva DFO, Costa KTDS, et al. Prevalence of comorbidities in deceased patients with COVID-19: a systematic review. Medicine (Baltimore). 2022 Sep 23;101(38):e30246.Full text  Abstract

884. Qian Z, Lu S, Luo X, et al. Mortality and clinical interventions in critically ill patient with coronavirus disease 2019: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Jul 23;8:635560.Full text  Abstract

885. Chandel A, Leazer S, Alcover KC, et al. Intensive care and organ support related mortality in patients with COVID-19: a systematic review and meta-analysis. Crit Care Explor. 2023 Mar;5(3):e0876.Full text  Abstract

886. Docherty AB, Mulholland RH, Lone NI, et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021 Jul;9(7):773-85.Full text  Abstract

887. Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. Thorax. 2022 Nov;77(11):1113-20.Full text  Abstract

888. Asch DA, Sheils NE, Islam MN, et al. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Intern Med. 2021 Apr 1;181(4):471-8.Full text  Abstract

889. Nguyen NT, Chinn J, Nahmias J, et al. Outcomes and mortality among adults hospitalized with COVID-19 at US medical centers. JAMA Netw Open. 2021 Mar 1;4(3):e210417.Full text  Abstract

890. Finelli L, Gupta V, Petigara T, et al. Mortality among US patients hospitalized with SARS-CoV-2 infection in 2020. JAMA Netw Open. 2021 Apr 1;4(4):e216556.Full text  Abstract

891. Anesi GL, Jablonski J, Harhay MO, et al. Characteristics, outcomes, and trends of patients with COVID-19-related critical illness at a learning health system in the United States. Ann Intern Med. 2021 May;174(5):613-21.Full text  Abstract

892. Baptista A, Vieira AM, Capela E, et al. COVID-19 fatality rates in hospitalized patients: a new systematic review and meta-analysis. J Infect Public Health. 2023 Oct;16(10):1606-12.Full text  Abstract

893. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: an overview of systematic evaluations. Eur J Clin Invest. 2021 Mar 26:e13554.Full text  Abstract

894. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling elderly populations. Eur J Epidemiol. 2022 Mar;37(3):235-49.Full text  Abstract

895. Centers for Disease Control and Prevention. COVID-19 pandemic planning scenarios. Mar 2021 [internet publication].Full text

896. Rajgor DD, Lee MH, Archuleta S, et al. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020 Jul;20(7):776-7.Full text  Abstract

897. Ghayda RA, Lee KH, Han YJ, et al. The global case fatality rate of coronavirus disease 2019 by continents and national income: a meta-analysis. J Med Virol. 2022 Jun;94(6):2402-13.Full text  Abstract

898. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, et al. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021 Jun;62(2):E311-20.Full text  Abstract

899. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51.Full text  Abstract

900. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020 Jun;20(6):669-77.Full text  Abstract

901. Sorbello M, El-Boghdadly K, Di Giacinto I, et al. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice. Anaesthesia. 2020 Jun;75(6):724-32.Full text  Abstract

902. Bixler D, Miller AD, Mattison CP, et al. SARS-CoV-2–associated deaths among persons aged <21 years: United States, February 12–July 31, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep 18;69(37):1324-9.Full text  Abstract

903. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6;323(16):1574-81.Full text  Abstract

904. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020 Mar 19;323(16):1612-4.Full text  Abstract

905. Kim K, Cho K, Song J, et al. The case fatality rate of COVID-19 during the Delta and the Omicron epidemic phase: a meta-analysis. J Med Virol. 2023 Feb;95(2):e28522. Abstract

906. Ahmad SJ, Degiannis JR, Borucki J, et al. Fatality rates after infection with the Omicron variant (B.1.1.529): how deadly has it been? A systematic review and meta-analysis. J Acute Med. 2024 Jun 1;14(2):51-60. Abstract

907. Centre for Evidence-Based Medicine; Oke J, Heneghan C. Global COVID-19 case fatality rates. Mar 2020 [internet publication].Full text

908. Mahase E. Covid-19: the problems with case counting. BMJ. 2020 Sep 3;370:m3374.Full text  Abstract

909. Centre for Evidence-Based Medicine; Spencer E, Jefferson T, Brassey J, et al. When is Covid, Covid? Sep 2020 [internet publication].Full text

910. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020 May 12;323(18):1775-6.Full text  Abstract

911. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS One. 2020;15(11):e0241955.Full text  Abstract

912. Booth A, Reed AB, Ponzo S, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021 Mar 4;16(3):e0247461.Full text  Abstract

913. Zhang L, Hou J, Ma FZ, et al. The common risk factors for progression and mortality in COVID-19 patients: a meta-analysis. Arch Virol. 2021 Aug;166(8):2071-87.Full text  Abstract

914. Dumitrascu F, Branje KE, Hladkowicz ES, et al. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021 Sep;69(9):2419-29.Full text  Abstract

915. Bellou V, Tzoulaki I, van Smeden M, et al. Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis. Eur Respir J. 2022 Feb 3;59(2):2002964.Full text  Abstract

916. Santus P, Radovanovic D, Saderi L, et al. Severity of respiratory failure at admission and in-hospital mortality in patients with COVID-19: a prospective observational multicentre study. BMJ Open. 2020 Oct 10;10(10):e043651.Full text  Abstract

917. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.Full text  Abstract

918. Javanmardi F, Keshavarzi A, Akbari A, et al. Prevalence of underlying diseases in died cases of COVID-19: a systematic review and meta-analysis. PLoS One. 2020 Oct 23;15(10):e0241265.Full text  Abstract

919. Shi Q, Wang Z, Liu J, et al. Risk factors for poor prognosis in children and adolescents with COVID-19: a systematic review and meta-analysis. EClinicalMedicine. 2021 Nov;41:101155.Full text  Abstract

920. Ramzi ZS. Hospital readmissions and post-discharge all-cause mortality in COVID-19 recovered patients: a systematic review and meta-analysis. Am J Emerg Med. 2022 Jan;51:267-79.Full text  Abstract

921. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020 Dec 3;383(23):2291-3.Full text  Abstract

922. Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021 Oct;21(10):1373-82.Full text  Abstract

923. UK Health Security Agency. COVID-19: investigation and management of suspected SARS-CoV-2 reinfections. Mar 2021 [internet publication].Full text

924. Mao YJ, Wang WW, Ma J, et al. Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis. Chin Med J (Engl). 2021 Dec 13;135(2):145-52.Full text  Abstract

925. Helfand M, Fiordalisi C, Wiedrick J, et al. Risk for reinfection after SARS-CoV-2: a living, rapid review for American College of Physicians practice points on the role of the antibody response in conferring immunity following SARS-CoV-2 infection. Ann Intern Med. 2022 Apr;175(4):547-55.Full text  Abstract

926. Roskosky M, Borah BF, DeJonge PM, et al. Notes from the field: SARS-CoV-2 omicron variant infection in 10 persons within 90 days of previous SARS-CoV-2 Delta variant infection - four states, October 2021 – January 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 8;71(14):524-6.Full text  Abstract

927. Flacco ME, Acuti Martellucci C, Baccolini V, et al. Risk of reinfection and disease after SARS-CoV-2 primary infection: meta-analysis. Eur J Clin Invest. 2022 Oct;52(10):e13845.Full text  Abstract

928. Nguyen NN, Nguyen YN, Hoang VT, et al. SARS-CoV-2 reinfection and severity of the disease: a systematic review and meta-analysis. Viruses. 2023 Apr 14;15(4):967.Full text  Abstract

929. Stephens DS, McElrath MJ. COVID-19 and the path to immunity. JAMA. 2020 Oct 6;324(13):1279-81.Full text  Abstract

930. World Health Organization. COVID-19 natural immunity: scientific brief. May 2021 [internet publication].Full text

931. Savage HR, Santos VS, Edwards T, et al. Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021 Jul 8;15(7):e0009551.Full text  Abstract

932. Arkhipova-Jenkins I, Helfand M, Armstrong C, et al. Antibody response after SARS-CoV-2 infection and implications for immunity: a rapid living review. Ann Intern Med. 2021 Jun;174(6):811-21.Full text  Abstract

933. Flannery DD, Gouma S, Dhudasia MB, et al. Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios. JAMA Pediatr. 2021 Jun 1;175(6):594-600.Full text  Abstract

934. Centre for Evidence-Based Medicine; Plüddemann A, Aronson JK. What is the role of T cells in COVID-19 infection? Why immunity is about more than antibodies. Oct 2020 [internet publication].Full text

935. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063.Full text  Abstract

936. Shrotri M, van Schalkwyk MCI, Post N, et al. T cell response to SARS-CoV-2 infection in humans: a systematic review. PLoS One. 2021;16(1):e0245532.Full text  Abstract

937. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. Cell Rep Med. 2021 Jul 20;2(7):100355.Full text  Abstract

938. Redd AD, Nardin A, Kared H, et al. CD8+ T-cell responses in COVID-19 convalescent individuals target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum Infect Dis. 2021 Jul;8(7):ofab143.Full text  Abstract

939. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. Lancet Microbe. 2022 May;3(5):e348-56.Full text  Abstract

940. Venet F, Gossez M, Bidar F, et al. T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19. EBioMedicine. 2022 Mar 26;78:103967.Full text  Abstract

941. Petráš M. Highly effective naturally acquired protection against COVID-19 persists for at least 1 year: a meta-analysis. J Am Med Dir Assoc. 2021 Nov;22(11):2263-5.Full text  Abstract

942. Chen Q, Zhu K, Liu X, et al. The protection provided by naturally acquired antibodies against subsequent SARS-CoV-2 infection: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Feb 23:1-44.Full text  Abstract

943. COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023 Mar 11;401(10379):833-42.Full text  Abstract

944. Hansen CH, Friis NU, Bager P, et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark. Lancet Infect Dis. 2023 Feb;23(2):167-76.Full text  Abstract

945. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Protective effect of previous SARS-CoV-2 infection against Omicron BA.4 and BA.5 subvariants. N Engl J Med. 2022 Oct 27;387(17):1620-2.Full text  Abstract

946. Chemaitelly H, Ayoub HH, Coyle P, et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nat Commun. 2022 Aug 9;13(1):4675.Full text  Abstract

947. Chemaitelly H, Ayoub HH, Tang P, et al. Immune imprinting and protection against repeat reinfection with SARS-CoV-2. N Engl J Med. 2022 Nov 3;387(18):1716-8.Full text  Abstract

948. Doshi P. Covid-19: do many people have pre-existing immunity? BMJ. 2020 Sep 17;370:m3563.Full text  Abstract

949. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020 Dec 11;370(6522):1339-43.Full text  Abstract

950. Ng RWY, Boon SS, Chen Z, et al. Cross-clade memory immunity in adults following SARS-CoV-1 infection in 2003. JAMA Netw Open. 2022 Dec 1;5(12):e2247723.Full text  Abstract

951. Shenai MB, Rahme R, Noorchashm H. Equivalency of protection from natural immunity in COVID-19 recovered versus fully vaccinated persons: a systematic review and pooled analysis. Cureus. 2021 Oct 28;13(10):e19102.Full text  Abstract

952. Chemaitelly H, Nagelkerke N, Ayoub HH, et al. Duration of immune protection of SARS-CoV-2 natural infection against reinfection. J Travel Med. 2022 Dec 27;29(8):taac109.Full text  Abstract

953. Chemaitelly H, Ayoub HH, AlMukdad S, et al. Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. Lancet Microbe. 2022 Dec;3(12):e944-55.Full text  Abstract

954. Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023 May;23(5):556-67.Full text  Abstract

955. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023 Sep;95:104734.Full text  Abstract

956. Heesakkers H, van der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA. 2022 Feb 8;327(6):559-65.Full text  Abstract

957. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost. 2020 Jul;18(7):1747-51.Full text  Abstract

958. Gendron N, Dragon-Durey MA, Chocron R, et al. Lupus anticoagulant single positivity during the acute phase of COVID-19 is not associated with venous thromboembolism or in-hospital mortality. Arthritis Rheumatol. 2021 Nov;73(11):1976-85.Full text  Abstract

959. Tan BK, Mainbourg S, Friggeri A, et al. Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. Thorax. 2021 Oct;76(10):970-9.Full text  Abstract

960. Zaffanello M, Piacentini G, Nosetti L, et al. Thrombotic risk in children with COVID-19 infection: a systematic review of the literature. Thromb Res. 2021 Jul 16;205:92-8.Full text  Abstract

961. Centre for Evidence-Based Medicine; Kernohan A, Calderon M. What are the risk factors and effectiveness of prophylaxis for venous thromboembolism in COVID-19 patients? Jul 2020 [internet publication].Full text

962. Cui LY, Cheng WW, Mou ZW, et al. Risk factors for pulmonary embolism in patients with COVID-19: a systemic review and meta-analysis. Int J Infect Dis. 2021 Aug 18;111:154-63.Full text  Abstract

963. Zuin M, Barco S, Giannakoulas G, et al. Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J Thromb Thrombolysis. 2023 Apr;55(3):490-8.Full text  Abstract

964. Massoud GP, Hazimeh DH, Amin G, et al. Risk of thromboembolic events in non-hospitalized COVID-19 patients: a systematic review. Eur J Pharmacol. 2023 Feb 15;941:175501.Full text  Abstract

965. van Nieuwkoop C. COVID-19 associated pulmonary thrombosis. Thromb Res. 2020 Jul;191:151.Full text  Abstract

966. Belen-Apak FB, Sarıalioğlu F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020 Aug;50(2):278-80.Full text  Abstract

967. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020 Jun 16;75(23):2950-73.Full text  Abstract

968. Bilaloglu S, Aphinyanaphongs Y, Jones S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020 Aug 25;324(8):799-801.Full text  Abstract

969. Woller SC, de Wit K, Robert-Ebadi H, et al. A systematic review of biomarkers among hospitalized patients with COVID-19 predictive of venous thromboembolism: a communication from the Predictive and Diagnostic Variables Scientific and Standardization Committee of the ISTH. Res Pract Thromb Haemost. 2022 Aug;6(6):e12786.Full text  Abstract

970. Wang C, Zhang H, Zhou M, et al. Prognosis of COVID-19 in patients with vein thrombosis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):10279-85.Full text  Abstract

971. Sabatino J, De Rosa S, Di Salvo G, et al. Impact of cardiovascular risk profile on COVID-19 outcome: a meta-analysis. PLoS One. 2020 Aug 14;15(8):e0237131.Full text  Abstract

972. Rezel-Potts E, Douiri A, Sun X, et al. Cardiometabolic outcomes up to 12 months after COVID-19 infection: a matched cohort study in the UK. PLoS Med. 2022 Jul;19(7):e1004052.Full text  Abstract

973. Jafari-Oori M, Moradian ST, Ebadi A, et al. Incidence of cardiac complications following COVID-19 infection: an umbrella meta-analysis study. Heart Lung. 2022 Jan 10;52:136-45.Full text  Abstract

974. Changal K, Veria S, Mack S, et al. Myocardial injury in hospitalized COVID-19 patients: a retrospective study, systematic review, and meta-analysis. BMC Cardiovasc Disord. 2021 Dec 31;21(1):626.Full text  Abstract

975. Tolu-Akinnawo O, Adusei Poku F, Elimihele T, et al. Acute cardiovascular complications of COVID-19: a systematic review. Cureus. 2023 May;15(5):e38576.Full text  Abstract

976. Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020 Jul 1;5(7):831-40.Full text  Abstract

977. Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020 Jul 7;142(1):68-78.Full text  Abstract

978. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation. 2020 Jun 9;141(23):1903-14.Full text  Abstract

979. Li X, Pan X, Li Y, et al. Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic review. Crit Care. 2020 Jul 28;24(1):468.Full text  Abstract

980. Xiong TY, Redwood S, Prendergast B, et al. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020 May 14;41(19):1798-800.Full text  Abstract

981. Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022 Mar;28(3):583-90.Full text  Abstract

982. Ng PY, Ip A, Ng AK, et al. Risk of acute kidney injury in critically-ill patients with COVID-19 compared with seasonal influenza: a retrospective cohort study. EClinicalMedicine. 2024 Apr;70:102535.Full text  Abstract

983. Raina R, Mahajan ZA, Vasistha P, et al. Incidence and outcomes of acute kidney injury in COVID-19: a systematic review. Blood Purif. 2021 Jun 15:1-14.Full text  Abstract

984. Cai X, Wu G, Zhang J, et al. Risk factors for acute kidney injury in adult patients with COVID-19: a systematic review and meta-analysis. Front Med (Lausanne). 2021 Dec 6;8:719472.Full text  Abstract

985. Vivaldi G, Pfeffer PE, Talaei M, et al. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023 Nov;65:102251.Full text  Abstract

986. World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Oct 2021 [internet publication].Full text

987. Centers for Disease Control and Prevention. Clinical overview of long COVID. Jun 2024 [internet publication].Full text

988. Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022 Aug;28(8):1706-14.Full text  Abstract

989. Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020 Aug 11;370:m3026.Full text  Abstract

990. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021 Sep;6(9):e005427.Full text  Abstract

991. Zhang X, Wang F, Shen Y, et al. Symptoms and health outcomes among survivors of COVID-19 infection 1 year after discharge from hospitals in Wuhan, China. JAMA Netw Open. 2021 Sep 1;4(9):e2127403.Full text  Abstract

992. American Academy of Physical Medicine and Rehabilitation. Multidisciplinary quality improvement initiative. 2023 [internet publication].Full text

993. Truong DT, Dionne A, Muniz JC, et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults. Circulation. 2022 Feb;145(5):345-56.Full text  Abstract

994. Gundry SR. Abstract 10712: MRNA COVID vaccines dramatically increase endothelial inflammatory markers and ACS risk as measured by the PULS cardiac test: a warning. Circulation. 2021 Nov 16;144 (Suppl 1):A10712.Full text

995. Pillay J, Gaudet L, Wingert A, et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ. 2022 Jul 13;378:e069445.Full text  Abstract

996. Hulscher N, Hodkinson R, Makis W, et al. Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis. ESC Heart Fail. 2024 Jan 14 [Epub ahead of print].Full text  Abstract

997. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022 Feb;28(2):410-22.Full text  Abstract

998. European Medicines Agency. COVID-19 vaccines safety update: 17 June 2022. Jun 2022 [internet publication].Full text

999. Hause AM, Baggs J, Marquez P, et al. COVID-19 vaccine safety in children aged 5-11 years: United States, November 3 – December 19, 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 31;70(5152):1755-60.Full text  Abstract

1000. Hause AM, Baggs J, Marquez P, et al. Safety monitoring of Pfizer-BioNTech COVID-19 vaccine booster doses among children aged 5-11 years: United States, May 17 - July 31, 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 19;71(33):1047-51.Full text  Abstract

1001. Lane S, Yeomans A, Shakir S. Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination. BMJ Open. 2022 Jul 1;12(7):e060425.Full text  Abstract

1002. Alami A, Krewski D, Farhat N, et al. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open. 2023 Jun 20;13(6):e065687.Full text  Abstract

1003. UK Health Security Agency. Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals. Jan 2023 [internet publication].Full text

1004. Matar RH, Mansour R, Nakanishi H, et al. Clinical characteristics of patients with myocarditis following COVID-19 mRNA vaccination: a systematic review and meta-analysis. J Clin Med. 2022 Aug 3;11(15):4521.Full text  Abstract

1005. Kracalik I, Oster ME, Broder KR, et al. Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance study. Lancet Child Adolesc Health. 2022 Nov;6(11):788-98.Full text  Abstract

1006. Cho JY, Kim KH, Lee N, et al. COVID-19 vaccination-related myocarditis: a Korean nationwide study. Eur Heart J. 2023 Jun 25;44(24):2234-43.Full text  Abstract

1007. Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mrna vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada. JAMA Netw Open. 2022 Jun 1;5(6):e2218505.Full text  Abstract

1008. Li G, Yang Y, Gao D, et al. Is liver involvement overestimated in COVID-19 patients? A meta-analysis. Int J Med Sci. 2021;18(5):1285-96.Full text  Abstract

1009. Radivojevic A, Abu Jad AA, Ravanavena A, et al. A systematic review of SARS-CoV-2-associated hepatic dysfunction and the impact on the clinical outcome of COVID-19. Cureus. 2022 Jul;14(7):e26852.Full text  Abstract

1010. Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep. 2021 May 19;11(1):10599.Full text  Abstract

1011. Alqahtani SA, Schattenberg JM. Liver injury in COVID-19: the current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-19.Full text  Abstract

1012. Sodeifian F, Seyedalhosseini ZS, Kian N, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021 Sep 20;8:731436.Full text  Abstract

1013. Wong GL, Wong VW, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. Lancet Gastroenterol Hepatol. 2020 Aug;5(8):776-87.Full text  Abstract

1014. Guerrero JI, Barragán LA, Martínez JD, et al. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis. 2021 Jun 2;21(1):515.Full text  Abstract

1015. Ali SS, Mumtaz A, Qamar MA, et al. New-onset Parkinsonism as a Covid-19 infection sequela: a systematic review and meta-analysis. Ann Med Surg (Lond). 2022 Aug;80:104281.Full text  Abstract

1016. Williams LD, Zis P. COVID-19-related burning eye syndrome and burning mouth syndrome: a systematic review and meta-analysis. Pain Ther. 2023 Mar 14;1-10.Full text  Abstract

1017. Favas TT, Dev P, Chaurasia RN, et al. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020 Dec;41(12):3437-70.Full text  Abstract

1018. Sullivan BN, Fischer T. Age-associated neurological complications of COVID-19: a systematic review and meta-analysis. Front Aging Neurosci. 2021 Aug 2;13:653694.Full text  Abstract

1019. Chua TH, Xu Z, King NKK. Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020 Oct 19:1-20. Abstract

1020. Kubota T, Kuroda N. Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. Clin Neurol Neurosurg. 2020 Nov 1;106349.Full text  Abstract

1021. Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients: an MRI-based 3-month follow-up study. EClinicalMedicine. 2020 Aug;25:100484.Full text  Abstract

1022. Taquet M, Sillett R, Zhu L, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022 Oct;9(10):815-27.Full text  Abstract

1023. LaRovere KL, Riggs BJ, Poussaint TY, et al. Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome. JAMA Neurol. 2021 May 1;78(5):536-47.Full text  Abstract

1024. Nagraj S, Varrias D, Hernandez Romero G, et al. Incidence of stroke in randomized trials of COVID-19 therapeutics: a systematic review and meta-analysis. Stroke. 2022 Nov;53(11):3410-8.Full text  Abstract

1025. Lu Y, Zhao JJ, Ye MF, et al. The relationship between COVID-19's severity and ischemic stroke: a systematic review and meta-analysis. Neurol Sci. 2021 Jul;42(7):2645-51.Full text  Abstract

1026. Yamakawa M, Kuno T, Mikami T, et al. Clinical characteristics of stroke with COVID-19: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020 Aug 29;29(12):105288.Full text  Abstract

1027. Nannoni S, de Groot R, Bell S, et al. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke. 2021 Feb;16(2):137-49.Full text  Abstract

1028. Valencia-Enciso N, Ortiz-Pereira M, Zafra-Sierra MP, et al. Time of stroke onset in coronavirus disease 2019 patients around the globe: a systematic review and analysis. J Stroke Cerebrovasc Dis. 2020 Sep 18;29(12):105325.Full text  Abstract

1029. Tu TM, Seet CYH, Koh JS, et al. Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men. JAMA Netw Open. 2021 Apr 1;4(4):e217498.Full text  Abstract

1030. Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke. 2020 Sep;51(9):e254-8.Full text  Abstract

1031. Qureshi AI, Abd-Allah F, Alsenani F, et al. Management of acute ischemic stroke in patients with COVID-19 infection: report of an international panel. Int J Stroke. 2020 Jul;15(5):540-54.Full text  Abstract

1032. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis. Eur J Neurol. 2021 Oct;28(10):3517-29.Full text  Abstract

1033. Abu-Rumeileh S, Abdelhak A, Foschi M, et al. Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol. 2021 Apr;268(4):1133-70.Full text  Abstract

1034. Censi S, Bisaccia G, Gallina S, et al. Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis. J Neurol. 2024 Mar;271(3):1063-71.Full text  Abstract

1035. Siow I, Lee KS, Zhang JJY, et al. Encephalitis as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol. 2021 Oct;28(10):3491-502.Full text  Abstract

1036. Nabizadeh F, Balabandian M, Sodeifian F, et al. Autoimmune encephalitis associated with COVID-19: a systematic review. Mult Scler Relat Disord. 2022 Apr 6;62:103795.Full text  Abstract

1037. Brown RL, Benjamin L, Lunn MP, et al. Pathophysiology, diagnosis, and management of neuroinflammation in covid-19. BMJ. 2023 Aug 18;382:e073923.Full text  Abstract

1038. Hayek SS, Brenner SK, Azam TU, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020 Sep 30;371:m3513.Full text  Abstract

1039. Khan DSA, Hamid LR, Ali A, et al. Differences in pregnancy and perinatal outcomes among symptomatic versus asymptomatic COVID-19-infected pregnant women: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2021 Dec 1;21(1):801.Full text  Abstract

1040. Deng J, Ma Y, Liu Q, et al. Association of infection with different SARS-CoV-2 variants during pregnancy with maternal and perinatal outcomes: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022 Nov 29;19(23):15932.Full text  Abstract

1041. Sheikh J, Lawson H, Allotey J, et al. Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country's income status: a meta-analysis. BMJ Glob Health. 2022 Nov;7(11):e010060.Full text  Abstract

1042. Simbar M, Nazarpour S, Sheidaei A. Evaluation of pregnancy outcomes in mothers with COVID-19 infection: a systematic review and meta-analysis. J Obstet Gynaecol. 2023 Dec;43(1):2162867.Full text  Abstract

1043. Sun S, Savitz DA, Wellenius GA. Changes in adverse pregnancy outcomes associated with the COVID-19 pandemic in the United States. JAMA Netw Open. 2021 Oct 1;4(10):e2129560.Full text  Abstract

1044. van Baar JAC, Kostova EB, Allotey J, et al. COVID-19 in pregnant women: a systematic review and meta-analysis on the risk and prevalence of pregnancy loss. Hum Reprod Update. 2024 Mar 1;30(2):133-52.Full text  Abstract

1045. Huntley BJF, Mulder IA, Di Mascio D, et al. Adverse pregnancy outcomes among individuals with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review and meta-analysis. Obstet Gynecol. 2021 Apr 1;137(4):585-96.Full text  Abstract

1046. Sturrock S, Ali S, Gale C, et al. Neonatal outcomes and indirect consequences following maternal SARS-CoV-2 infection in pregnancy: a systematic review. BMJ Open. 2023 Mar 15;13(3):e063052.Full text  Abstract

1047. Stowe J, Smith H, Thurland K, et al. Stillbirths during the COVID-19 pandemic in England, April-June 2020. JAMA. 2021 Jan 5;325(1):86-7.Full text  Abstract

1048. DeSisto CL, Wallace B, Simeone RM, et al. Risk for stillbirth among women with and without COVID-19 at delivery hospitalization: United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 26;70(47):1640-5.Full text  Abstract

1049. Magnus MC, Örtqvist AK, Urhoj SK, et al. Infection with SARS-CoV-2 during pregnancy and risk of stillbirth: a Scandinavian registry study. BMJ Public Health. 2023;1:e000314.Full text

1050. Smith ER, Oakley E, Grandner GW, et al. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. BMJ Glob Health. 2023 Jan;8(1):e009495.Full text  Abstract

1051. Jeong Y, Kim MA. The coronavirus disease 2019 infection in pregnancy and adverse pregnancy outcomes: a systematic review and meta-analysis. Obstet Gynecol Sci. 2023 Jul;66(4):270-89.Full text  Abstract

1052. Dhir SK, Kumar J, Meena J, et al. Clinical features and outcome of SARS-CoV-2 infection in neonates: a systematic review. J Trop Pediatr. 2021 Jul 2;67(3):fmaa059.Full text  Abstract

1053. Allotey J, Chatterjee S, Kew T, et al. SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis. BMJ. 2022 Mar 16;376:e067696.Full text  Abstract

1054. Meng X, Zhu K, Wang J, et al. Can SARS-CoV-2 positive pregnant women affect the hearing of their newborns: a systematic review. Am J Otolaryngol. 2022 Jun 2;43(5):103523.Full text  Abstract

1055. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, et al. Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis. Crit Care Med. 2021 Dec 1;49(12):2042-57.Full text  Abstract

1056. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020 Apr 20;7(1):19.Full text  Abstract

1057. Zhou X, Cheng Z, Luo L, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021 Feb 17;201:23-9.Full text  Abstract

1058. Levi M, Iba T. COVID-19 coagulopathy: is it disseminated intravascular coagulation? Intern Emerg Med. 2021 Mar;16(2):309-12.Full text  Abstract

1059. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033-40.Full text  Abstract

1060. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-9.Full text  Abstract

1061. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-6.Full text  Abstract

1062. Azagew AW, Beko ZW, Ferede YM, et al. Global prevalence of COVID-19-induced acute respiratory distress syndrome: systematic review and meta-analysis. Syst Rev. 2023 Nov 13;12(1):212.Full text  Abstract

1063. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. Pediatrics. 2020 Jun;145(6):e20200702.Full text  Abstract

1064. Jain S, Khanna P, Sarkar S. Comparative evaluation of ventilator-associated pneumonia in critically ill COVID- 19 and patients infected with other corona viruses: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2021 Sep 28;92(2).Full text  Abstract

1065. Singh A, Singh Y, Pangasa N, et al. Risk factors, clinical characteristics, and outcome of air leak syndrome in COVID-19: a systematic review. Indian J Crit Care Med. 2021 Dec;25(12):1434-45.Full text  Abstract

1066. Que Y, Hu C, Wan K, et al. Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2021 Feb 22;1-14.Full text  Abstract

1067. Qamar MA, Afzal SS, Dhillon RA, et al. A global systematic review and meta-analysis on the emerging evidence on risk factors, clinical characteristics, and prognosis of multisystem inflammatory syndrome in adults (MIS-A). Ann Med Surg (Lond). 2023 Sep;85(9):4463-75.Full text  Abstract

1068. Abrams JY, Godfred-Cato SE, Oster ME, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review. J Pediatr. 2020 Aug 5;226:45-54.Full text  Abstract

1069. Royal College of Paediatrics and Child Health. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS): national consensus management pathway. Sep 2020 [internet publication].Full text

1070. Yousaf AR, Cortese MM, Taylor AW, et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022 May;6(5):303-12.Full text  Abstract

1071. Ouldali N, Bagheri H, Salvo F, et al. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study. Lancet Reg Health Eur. 2022 Apr 29:100393.Full text  Abstract

1072. Kildegaard H, Lund LC, Højlund M, et al. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study. BMJ. 2022 Apr 11;377:e068898.Full text  Abstract

1073. Ward JL, Harwood R, Kenny S, et al. Pediatric hospitalizations and ICU admissions due to COVID-19 and pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 in England. JAMA Pediatr. 2023 Jul 31;177(9):947-55.Full text  Abstract

1074. Yousaf AR, Lindsey KN, Wu MJ, et al. Notes from the field: surveillance for multisystem inflammatory syndrome in children - United States, 2023. MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):225-8.Full text  Abstract

1075. Abbas Q, Ali H, Amjad F, et al. Clinical presentation, diagnosis and management of multisystem inflammatory syndrome in children (MIS-C): a systematic review. BMJ Paediatr Open. 2024 Jun 6;8(1):e002344. Abstract

1076. Rhedin S, Lundholm C, Horne A, et al. Risk factors for multisystem inflammatory syndrome in children: a population-based cohort study of over 2 million children. Lancet Reg Health Eur. 2022 Aug;19:100443.Full text  Abstract

1077. Abrams JY, Oster ME, Godfred-Cato SE, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc Health. 2021 May;5(5):323-31.Full text  Abstract

1078. Shaiba LA, More K, Hadid A, et al. Multisystemic inflammatory syndrome in neonates: a systematic review. Neonatology. 2022 May 5:1-13.Full text  Abstract

1079. Lopez L, Burgner D, Glover C, et al. Lower risk of multi-system inflammatory syndrome in children (MIS-C) with the omicron variant. Lancet Reg Health West Pac. 2022 Oct;27:100604.Full text  Abstract

1080. Haghighi Aski B, Manafi Anari A, Abolhasan Choobdar F, et al. Cardiac abnormalities due to multisystem inflammatory syndrome temporally associated with Covid-19 among children: a systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2021 Mar 22:100764.Full text  Abstract

1081. Tripathi AK, Pilania RK, Bhatt GC, et al. Acute kidney injury following multisystem inflammatory syndrome associated with SARS-CoV-2 infection in children: a systematic review and meta-analysis. Pediatr Nephrol. 2023 Feb;38(2):357-70.Full text  Abstract

1082. Zou H, Lu J, Liu J, et al. Characteristics of pediatric multi-system inflammatory syndrome (PMIS) associated with COVID-19: a meta-analysis and insights into pathogenesis. Int J Infect Dis. 2021 Jan;102:319-26.Full text  Abstract

1083. Tong T, Yao X, Lin Z, et al. Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. Pediatr Rheumatol Online J. 2022 Dec 5;20(1):112.Full text  Abstract

1084. Levy N, Koppel JH, Kaplan O, et al. Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel. JAMA. 2022 Jun 28;327(24):2452-4.Full text  Abstract

1085. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022 Apr;74(4):e1-20.Full text  Abstract

1086. Davies P, du Pré P, Lillie J, et al. One-year outcomes of critical care patients post-COVID-19 multisystem inflammatory syndrome in children. JAMA Pediatr. 2021 Dec 1;175(12):1281-3.Full text  Abstract

1087. Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health. 2021 Jul;5(7):473-82.Full text  Abstract

1088. Bilotta C, Perrone G, Adelfio V, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021 Nov 29;12:729251.Full text  Abstract

1089. Waqar U, Ahmed S, Gardezi SMHA, et al. Thrombosis with thrombocytopenia syndrome after administration of AZD1222 or Ad26.COV2.S vaccine for COVID-19: a systematic review. Clin Appl Thromb Hemost. Jan-Dec 2021 Jan-Dec;27:10760296211068487.Full text  Abstract

1090. Rizk JG, Gupta A, Sardar P, et al. Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review. JAMA Cardiol. 2021 Dec 1;6(12):1451-60.Full text  Abstract

1091. Hafeez MU, Ikram M, Shafiq Z, et al. COVID-19 vaccine-associated thrombosis with thrombocytopenia syndrome (TTS): a systematic review and post hoc analysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211048815.Full text  Abstract

1092. Dag Berild J, Bergstad Larsen V, Myrup Thiesson E, et al. Analysis of thromboembolic and thrombocytopenic events after the AZD1222, BNT162b2, and MRNA-1273 COVID-19 vaccines in 3 Nordic countries. JAMA Netw Open. 2022 Jun 1;5(6):e2217375.Full text  Abstract

1093. Andrews NJ, Stowe J, Ramsay ME, et al. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Health Eur. 2022 Feb;13:100260.Full text  Abstract

1094. See I, Lale A, Marquez P, et al. Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination: United States, December 2020 to August 2021. Ann Intern Med. 2022 Apr;175(4):513-22.Full text  Abstract

1095. Pavord S, Scully M, Hunt BJ, et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med. 2021 Oct 28;385(18):1680-9.Full text  Abstract

1096. World Health Organization. Interim statement of the COVID-19 subcommittee of the WHO global advisory committee on vaccine safety on AstraZeneca COVID-19 vaccine. Apr 2021 [internet publication].Full text

1097. National Institute for Health and Care Excellence. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). Jun 2022 [internet publication].Full text

1098. Palaiodimou L, Stefanou MI, Katsanos AH, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: a systematic review and meta-analysis. Neurology. 2021 Nov 23;97(21):e2136-47. Abstract

1099. Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, et al. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: a systematic review. J Neurol Sci. 2021 Aug 3;428:117607.Full text  Abstract

1100. Salih F, Schönborn L, Kohler S, et al. Vaccine-induced thrombocytopenia with severe headache. N Engl J Med. 2021 Nov 25;385(22):2103-5.Full text  Abstract

1101. Cascio Rizzo A, Giussani G, Agostoni EC. Ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia following COVID-19 vaccine: a case report with systematic review of the literature. Cerebrovasc Dis. 2022 May 5:1-13. Abstract

1102. Kolahchi Z, Khanmirzaei M, Mowla A. Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review. J Neurol Sci. 2022 Jun 20;439:120327.Full text  Abstract

1103. British Society for Haematology. Guidance from the expert haematology panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis (VITT). Sep 2021 [internet publication].Full text

1104. American Society of Hematology. Vaccine-induced immune thrombotic thrombocytopenia. May 2022 [internet publication].Full text

1105. Furie KL, Cushman M, Elkind MSV, et al; American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021 Jul;52(7):2478-82.Full text  Abstract

1106. International Society on Thrombosis and Haemostasis. The ISTH releases interim guidance on vaccine-induced immune thrombotic thrombocytopenia (VITT). Apr 2021 [internet publication].Full text

1107. World Health Organization. ​Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Apr 2023 [internet publication].Full text

1108. Hwang J, Park SH, Lee SW, et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score. Eur Heart J. 2021 Oct 14;42(39):4053-63.Full text  Abstract

1109. Mani A, Ojha V. Thromboembolism after COVID-19 vaccination: a systematic review of such events in 286 patients. Ann Vasc Surg. 2022 Aug;84:12-20.Full text  Abstract

1110. Botton J, Jabagi MJ, Bertrand M, et al. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France. Ann Intern Med. 2022 Sep;175(9):1250-7.Full text  Abstract

1111. Mitaka H, Kuno T, Takagi H, et al. Incidence and mortality of COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Mycoses. 2021 Sep;64(9):993-1001.Full text  Abstract

1112. Wang J, Yang Q, Zhang P, et al. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020 Jun 5;24(1):299.Full text  Abstract

1113. Hurt W, Youngs J, Ball J, et al. COVID-19-associated pulmonary aspergillosis in mechanically ventilated patients: a prospective, multicentre UK study. Thorax. 2023 Dec 15;79(1):75-82.Full text  Abstract

1114. Gioia F, Walti LN, Orchanian-Cheff A, et al. Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis. Lancet Respir Med. 2024 Mar;12(3):207-16. Abstract

1115. Hong W, White PL, Backx M, et al. CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis. Clin Imaging. 2022 Oct;90:11-18.Full text  Abstract

1116. Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jul;3(7):e543-52.Full text  Abstract

1117. Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect Dis. 2022 Sep;22(9):e240-53.Full text  Abstract

1118. Özbek L, Topçu U, Manay M, et al. COVID-19-associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect. 2023 Jun;29(6):722-31.Full text  Abstract

1119. Muthu V, Rudramurthy SM, Chakrabarti A, et al. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia. 2021 Dec;186(6):739-54.Full text  Abstract

1120. Dulski TM, DeLong M, Garner K, et al. Notes from the field: COVID-19-associated mucormycosis – Arkansas, July–September 2021. MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1750-1.Full text  Abstract

1121. Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. Mycoses. 2021 Dec;64(12):1452-9.Full text  Abstract

1122. Singh AK, Singh R, Joshi SR, et al. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021 May 21;15(4):102146.Full text  Abstract

1123. Indian Council of Medical Research. Evidence based advisory in the time of COVID-19 (screening, diagnosis and management of mucormycosis). 2021 [internet publication].Full text

1124. Arora N, Gudipati A, Kundu R, et al. Post-COVID-19 mucormycosis presenting as chest wall cellulitis with mediastinitis. Lancet Infect Dis. 2021 Nov;21(11):1611.Full text  Abstract

1125. Kumar A. Mucormycosis in COVID-19 recovered patients. J Med Virol. 2022 Apr;94(4):1272-3.Full text  Abstract

1126. Pruthi H, Muthu V, Bhujade H, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary mucormycosis: case series and systematic review of the literature. Mycopathologia. 2022 Feb;187(1):31-7.Full text  Abstract

1127. Ostovan VR, Tabrizi R, Bazrafshan H, et al. Mortality-related risk factors for coronavirus disease (COVID-19)-associated mucormycosis: a systematic review and meta-analysis. Curr Fungal Infect Rep. 2022 Aug 11:1-11.Full text  Abstract

1128. Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA): from immunology to treatment. J Fungi (Basel). 2020 Jun 24;6(2):91.Full text  Abstract

1129. Prestel C, Anderson E, Forsberg K, et al. Candida auris outbreak in a COVID-19 specialty care unit: Florida, July – August 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):56-7.Full text  Abstract

1130. Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022 Feb;10(2):180-90.Full text  Abstract

1131. Wang F, Wang H, Fan J, et al. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology. 2020 Apr 1;159(1):367-70.Full text  Abstract

1132. Mutneja HR, Bhurwal A, Arora S, et al. Acute pancreatitis in patients with COVID-19 is more severe and lethal: a systematic review and meta-analysis. Scand J Gastroenterol. 2021 Dec;56(12):1467-72. Abstract

1133. Yang F, Huang Y, Li T, et al. Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis. Gut. 2022 Jul;71(7):1451-3.Full text  Abstract

1134. Aziz AA, Aziz MA, Saleem M, et al. Acute pancreatitis related to COVID-19 infection: a systematic review and analysis of data. Cureus. 2022 Aug;14(8):e28380.Full text  Abstract

1135. Gubatan J, Levitte S, Patel A, et al. Prevalence, risk factors and clinical outcomes of COVID-19 in patients with a history of pancreatitis in Northern California. Gut. 2021 Feb;70(2):440-1.Full text  Abstract

1136. Babajide OI, Ogbon EO, Adelodun A, et al. COVID-19 and acute pancreatitis: a systematic review. JGH Open. 2022 Apr;6(4):231-5.Full text  Abstract

1137. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020 Sep 19:1-11.Full text  Abstract

1138. Meftah E, Rahmati R, Zari Meidani F, et al. Subacute thyroiditis following COVID-19: a systematic review. Front Endocrinol (Lausanne). 2023 Apr 15;14:1126637.Full text  Abstract

1139. Ganie MA, Rashid H, Qadir A, et al. Subacute thyroiditis in active COVID-19 infection: a report of two cases with a systematic review of the literature. Cureus. 2024 Jan;16(1):e52611.Full text  Abstract

1140. Aemaz Ur Rehman M, Farooq H, Ali MM, et al. The association of subacute thyroiditis with COVID-19: a systematic review. SN Compr Clin Med. 2021 Apr 29:1-13.Full text  Abstract

1141. Tutal E, Ozaras R, Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med Infect Dis. 2022 Mar 18;47:102314.Full text  Abstract

1142. El Moheb M, Naar L, Christensen MA, et al. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 2020 Sep 24;324(18):1899-901.Full text  Abstract

1143. Ojha V, Mani A, Mukherjee A, et al. Mesenteric ischemia in patients with COVID-19: an updated systematic review of abdominal CT findings in 75 patients. Abdom Radiol (NY). 2021 Nov 10;1-38.Full text  Abstract

1144. Keshavarz P, Rafiee F, Kavandi H, et al. Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin Imaging. 2020 Dec 8;73:86-95.Full text  Abstract

1145. Patel S, Parikh C, Verma D, et al. Bowel ischemia in COVID-19: a systematic review. Int J Clin Pract. 2021 Oct 4:e14930.Full text  Abstract

1146. Marasco G, Maida M, Morreale GC, et al. Gastrointestinal bleeding in COVID-19 patients: a systematic review with meta-analysis. Can J Gastroenterol Hepatol. 2021 Sep 1;2021:2534975.Full text  Abstract

1147. Chen J, Hang Y. Characteristics, risk factors and outcomes of gastrointestinal hemorrhage in COVID-19 patients: a meta-analysis. Pak J Med Sci. 2021 Sep-Oct;37(5):1524-31.Full text  Abstract

1148. Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation. J Med Virol. 2022 Apr;94(4):1391-401.Full text  Abstract

1149. Christensen RE, Jafferany M. Association between alopecia areata and COVID-19: a systematic review. JAAD Int. 2022 Jun;7:57-61.Full text  Abstract

1150. Creta M, Sagnelli C, Celentano G, et al. SARS-CoV-2 infection affects the lower urinary tract and male genital system: a systematic review. J Med Virol. 2021 May;93(5):3133-42.Full text  Abstract

1151. Haghpanah A, Masjedi F, Salehipour M, et al. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms? A systematic review. Prostate Cancer Prostatic Dis. 2021 May 18;1-12.Full text  Abstract

1152. Xie Y, Mirzaei M, Kahrizi MS, et al. SARS-CoV-2 effects on sperm parameters: a meta-analysis study. J Assist Reprod Genet. 2022 Jul;39(7):1555-63.Full text  Abstract

1153. Bao J, Guo Z, He J, et al. Semen parameters and sex hormones as affected by SARS-CoV-2 infection: a systematic review. Prog Urol. 2022 Dec;32(16):1431-9.Full text  Abstract

1154. Raschke RA, Agarwal S, Rangan P, et al. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. JAMA. 2021 Apr 13;325(14):1469-70.Full text  Abstract

1155. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020 Nov;75(11):1009-16.Full text  Abstract

1156. Shah AS, Wong AW, Hague CJ, et al. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021 Apr;76(4):402-4.Full text  Abstract

1157. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021 Jul-Aug;27(4):328-37.Full text  Abstract

1158. Chen M, Liu J, Peng P, et al. Dynamic changes of pulmonary diffusion capacity in survivors of non-critical COVID-19 during the first six months. EClinicalMedicine. 2022 Jan;43:101255.Full text  Abstract

1159. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ. 2020 Apr 7;369:m1328.Full text  Abstract

1160. de Jong VMT, Rousset RZ, Antonio-Villa NE, et al. Clinical prediction models for mortality in patients with covid-19: external validation and individual participant data meta-analysis. BMJ. 2022 Jul 12;378:e069881.Full text  Abstract

1161. Cárdenas-Fuentes G, Bosch de Basea M, Cobo I, et al. Validity of prognostic models of critical COVID-19 is variable: a systematic review with external validation. J Clin Epidemiol. 2023 Jul;159:274-88.Full text  Abstract

1162. Centers for Disease Control and Prevention. Animals and COVID-19. Apr 2023 [internet publication].Full text

1163. Silva MJA, Santana DS, Lima MBM, et al. Assessment of the risk impact of SARS-CoV-2 infection prevalence between cats and dogs in America and Europe: a systematic review and meta-analysis. Pathogens. 2024 Apr 12;13(4):314.Full text  Abstract

1164. Salman D, Vishnubala D, Le Feuvre P, et al. Returning to physical activity after covid-19. BMJ. 2021 Jan 8;372:m4721.Full text  Abstract

1165. Daniels CJ, Rajpal S, Greenshields JT, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 Sep 1;6(9):1078-87.Full text  Abstract

1166. Lemes IR, Smaira FI, Ribeiro WJD, et al. Acute and post-acute COVID-19 presentations in athletes: a systematic review and meta-analysis. Br J Sports Med. 2022 Aug;56(16):941-7. Abstract

1167. Alosaimi B, AlFayyad I, Alshuaibi S, et al. Cardiovascular complications and outcomes among athletes with COVID-19 disease: a systematic review. BMC Sports Sci Med Rehabil. 2022 Apr 20;14(1):74.Full text  Abstract